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                                                     ABSTRACT 
Aim: Dengue is a major health problem and ranks as the most important mosquito 
borne viral disease in the world.Several factors have been attributed to increased 
morbidity and mortality in dengue with altered haematological and coagulation 
parameters playing an important role.The present study was done to analyze the  
haematological findings and correlate the same with the clinical course ,to evaluate 
the role of platelet count in predicting outcome in dengue patients and to observe the 
number of serologically  dengue positive patients requiring platelet transfusion and 
its outcome. 
Materials and Methods: Fifty patients admitted in Sree Mookambika Institute of 
Medical Sciences Hospital with fever and  IgM and or NS1 positivity were 
selected.Various haematological,biochemical and clinical parameters were studied 
along with  the role of platelet transfusion and the outcome noted.Statistical analysis 
was done for the various parameters. 
Results:Out of the 50 cases in this study all the cases had fever(100%),headache 
(100%),myalgia (86%) ,hepatomegaly (52%) and splenomegaly in (48%).26% had 
ascites,rise of haematocrit and pleural effusion was seen in 16% each.Leukopenia 
was seen in 73% of the cases ,reversal of neutrophil lymphocyte ratio was seen in 
27% of the cases. AST and ALT levels were raised with mean value being 106.08 
IU/L and 118.54 IU/L.Platelet transfusion was indicated 86% of the cases.52% of the 
cases were transfused platelets on the first day.54%of the cases had 1-2 units of 
platelets transfused. 53.49% of the patients took 3 days to recover 3 days after 
transfusion of platelets. 
Conclusion:Fever with headache and presence of 
thrombocytopenia,leukopenia,reversal of neutrophil lymphocyte ratio with signs of 
capillary leak like ascitis ,pleural effusion and rising haematocrit should raise strong 
suspicion of dengue fever.Platelet transfusion in cases of moderate to severe 
thrombocytopenia proved to be useful for an eventful and smooth recovery. 
Key words:Dengue,IgM,Thrombocytopenia,Leukopenia,reversal of neutrophil 
lymphocyte ratio, rising haematocrit,Platelet transfusion 
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 "The pains which accompanied this fever were exquisitely severe in the 
head, back and limbs.  The pains in the head were sometimes in the back parts 
of it, and at other times they occupied only the eyeballs.  In some people the 
pains were so acute in their backs and hips that they could not lie in bed… A 
few complained of their flesh being sore to touch, in every part of the body.  
From these circumstances, the disease was sometimes believed to be 
rheumatism.  But its more general name among all classes of people was Break 
– Bone fever." 
Benjamin Rush (1745-1813) 
 The name Dengue has an African origin.  The term 'dengue' is a Spanish 
adaptation at the swahill expression'Ki-Dinga pepo' meaning 'cramp like 
seizures caused by  evil spirits' reported during 19th century. Epidemics of 
illness compatible with dengue fever were first reported in medical literature in 
1779 in Butavia (present day Jakarta). It was also reported in 1780 in 
Philadelphia. 
 The Dengue virus was first isolated in the year 1943 and  Dengue fever 
(DF) has been recognized for at least several  hundred years.  
 The first reported epidemics of dengue illness occurred in 1779-1780 in 
Asia, Africa and North America.  The near concurrent incidence of outbreak in 
three continents shows that these viruses and their mosquito vectors have had 
a world wide circulation in the tropics for more than two hundred years.  For the 
duration of this time DF was considered a placid, nonfatal disease of visitors to 
the tropics. Usually, there were long intervals of 10-40 years between major 
epidemics chiefly because  the beginning of a new serotype in a at risk 
population occurred only if viruses and their mosquito vector could endure the 
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slow transportation. A pandemic of dengue began in South East Asia after 
World War II and has spread around the world. Since then Epidemics caused 
by multiple serotypes (Hyperendemictity) are more recurrent, the geographic 
circulation of dengue viruses and their mosquito vectors has extended and DHF 
has emerged in the Americas and the Pacific region. 
 The worldwide epidemiology of dengue fever / dengue haemorrhagic 
fever is changing fast.  The Indian encounter with this disease is fascinating and 
captivating.  In recent years the disease has distorted its course manifesting in 
the severe form as DHF and with increasing incidence of outbreaks.  
 The reasons for this revival are:  
1. Unparalleled growth of human populace. 
2. Unintended and unrestrained inhabitation  
3. Insufficient waste disposal and water supply 
4. Amplified circulation & density of vector mosquitoes.  
5. Lack of effective mosquito control procedures 
6. Increased progression and spread of dengue virus.  
Haematological parameters like Hb level, total WBC count, differential 
WBC count and platelet count are altered in dengue fever.  The most common 
findings are thrombocytopenia with concurrent haemoconcentration.   
A guide for analysis, treatment and containment of Dengue fever 
prepared by Technical Advisory Committee on Dengue Haemorrhagic fever for 
South East Asia Western Pacific areas in 1975 & 1980 has been modified by 
WHO.The criteria include 4 Major manifestations such as: 
I.  Major manifestations of fever 
II. Haemorrhagic manifestations  
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III. Hepatomegaly 
IV. Tendency to develop shock, two laboratory changes (ie) 
thrombocytopenia and concurrent haemoconcentration which 
have been proven to be practical for suspicion and subsequent 
screening in 95% cases.  
 
Other important  laboratory findings:  
1. Leucopenia 
2. Lymphocytosis with reactive Lymphocytes  
3. Increased capillary permeability  
4. Elevated liver enzymes 
Aberrant immune overactivation as well as dengue virus induced toxicity 
contributes to disease process.  Aberrant immune overactivation not only 
impairs clearance of virus but also results in: 
1) Overproduction of cytokines like TNF,TNF,TNF that affect 
monocytes, endothelial cell and hepatocyte functions.  
2) Abnormal overproduction of auto antibodies to platelets and endothelial 
cells through molecular mimicry to NS1, and prM antigens.  
 Dengue virus induced coagulopathy and vasculopathy and dengue virus 
associated inhibition of Megakaryopoiesis and apoptotic death of early 
megakayocytes progenitors also contribute to the pathogenesis.  
 An isolated platelet count of <50,000/µl is associated with minor risk of 
bleeding until the count drops below <1000-20,000/µl.  There is increased risk 
of bleeding when associated with coexisting coagulopathies, liver disease,  
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platelet inhibiting drugs and infection.  The minimum threshold for platelet 
transfusion is <10,000/µl in otherwise stable patients.  
 Today Dengue has positioned itself as the most important mosquito 
borne viral disease in the world.  Current estimates report that at least 112 
countries are endemic for Dengue and around 40% of the world population are 
at risk in tropics and subtropics.  Annually around 100 million cases of dengue 
fever and half a million cases of DHF occurs world wide.  Early recognition and 
prompt initiation of  treatment  and platelet transfusion  in indicated cases are 
imperative if disease related morbidity and mortality are to be restricted.  
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1. To analyze the hematological findings in dengue illness and to correlate the 
same with the clinical course. 
2. To evaluate the role of platelet count in predicting outcome in dengue 
patients. 
3. To observe the number of serologically dengue positive patients requiring 
platelet transfusion and observe its outcome 
 
 
REVIEW OF LITERATURE 
 
6 | P a g e  
 
History: 
 The word “Dengue”has  an African origin1,2,7. The term "break-bone 
fever" was coined by Benjamin Rush who described dengue during an epidemic 
occurring in Philadelphia in 1780. Dengue epidemics are acknowledged to have 
occurred over the last three centuries in humid, subtropical and temperate 
places around the earth. A disease epidemic attuned with dengue was reported 
in China as early on as 992 AD, but the first outbreak of dengue was recorded 
in 1635 in the French West Indies.1 
 The earliest reported scourge of  DF occurred between 1779- 1780 in 
Asia, Africa and North America. During initial epidemics, dengue was thought of 
as a mild, non fatal disease and there were extended intervals between  the 
major outbreaks.1 
 A pandemic of DF started in  South East Asia subsequent to World War 
II and has extended around the world since then. In these regions epidemics of 
DHF started in emerge in the 1950's, but by 1975  had become a major reason 
of hospitalization and death. 1,2 
 Spread of dengue is now seen  in every World Health Organisation 
(WHO) region of the world and more than 125 countries are recognized to be 
dengue endemic. The exact impact of dengue internationally is difficult to 
establish due to factors such as poor disease scrutiny, misdiagnosis  and low 
level of coverage. Currently available data  grossly underestimates the societal, 
monetary and illness burden2. Every ten years the usual yearly number of cases 
of DF/ DHF  reported to WHO continues to raise exponentially.1From 2000 to 
2008, the typical yearly number of cases was 1,656,870 (or) nearly thrice the 
 
REVIEW OF LITERATURE 
 
7 | P a g e  
 
figure from 1990 – 1999, which was 4,79,848 of cases. In the year  2008, a 
record of 69 nations from the WHO regions of South –East Asia, Western  
Pacific and the Americas had  dengue.1,2A 2012 publication recommended that 
2.97 people living in 128 countries are at  risk of dengue internationally, 834 
million people in metropolitan residences and 763 million per cities. The same 
assemblage again in 2013 using cartographic approach said that  390 million 
dengue infections occur world wide.2,6 
All the four strains of dengue viruses are circulating in continents of Asia, 
Africa and the Americas. Owing to early recognition and better case 
management, reported case casualty rates have been lower in  the current 
years than in the decades before 2000.  
The burden of infirmity caused by dengue is calculated by a set of 
epidemiological indicators such as the number of clinical cases classified by 
relentlessness  of the disease (DF, DHF, DSS), duration of sickness period, 
value of life during the illness event,  fatal outcome rate and total number of 
deaths during a given time frame. All these epidemiological indications are 
united into a single health indicator, such as disability – adjusted life years 
(DALYS).1 
The South East Asia Region : 
Of the 25 billion citizens around the globe existing in dengue endemic 
nations and at risk of  having  DF/ DHF, 1.3 billion live in nations of the WHO 
South East Asia (SEA) region which are known for being dengue endemic 
areas. Epidemics continue to persist at expected 3-5 years cycles all over SEA. 
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Till  the year 2003, only eight nations in the area had reported dengue outbreak 
cases. By 2009, all countries except Korea had reported dengue outbreaks.1 
 The accounted for dengue cases and deaths from 1985 and  2009  in 10 
countries of the WHO- SEA nations highlight the public health magnitude of this 
disease in the region1.  
 The figure of dengue cases has amplified over the last three to four years 
with frequent epidemics1. Severe dengue is widespread in most SEA countries, 
with rates of severe dengue being 18 times high in this area compared with the 
Americas.2 
 In nations of the SEA region the tendency of dengue cases is showing an 
augment over the years. The case fatality rate (CFR), has however shown a 
waning tendency since 1985 and this is found to be accredited to better case 
management.1 
The Indian Scenario : 
 The  earliest epidemic of clinically suspicious dengue like fever was 
recorded at Chennai in 1780 and the first virologically proved outbreak of DF in 
India happened in Calcutta and  the Eastern Coast of India in the years 1963- 
1964. The initial chief outbreak of DF occurred in 1953- 1954 in Philippines 
followed by a rapid universal increase of epidemics of DHF/ DF. DHF was 
occurring in the neighboring countries but it was not present in India for 
mysterious reasons as all risk factors were present.6,8 
 The DHF had started emerging in different parts of India ever since 
1988.1,4 The first major extensive epidemics of DHF/ DSS occurred in India in 
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the year 1996 in areas around Delhi and Lucknow and then it widened to all 
over the country.4,8 
 The epidemiology of dengue illness in the Indian region has been very 
multifaceted and has considerably changed over approximately past six 
decades in conditions of prevalent strains, affected geographical setting and 
ruthlessness of the disease.4 The outbreak at Kanpur during the year 1968 was 
because of   DV-4 and during the 1969 epidemic both DV-4 and DV-2 strains 
were isolated.4 It was entirely replaced by the DV-2 Strain in 1970 outbreak in 
the adjoining city of Hardoi. DV-3 was isolated from the 1966 epidemic at 
Vellore and subsequently all 4 strains were isolated in 1968.  DV -2 was the 
principal serotype circulating in northern India especially Delhi, Lucknow and 
Gwalior. Phylogenetic analysis of DV-2 strain in Delhi during 1996 were 
genotype IV .Earlier isolates during 1957, and 1967 belonged to genotype V. 
DV-2 genotype IV has replaced genotype V, which continues to circulate mutely 
in North India and has the prospective to re-emerge and cause key epidemics 
of DF and DHF.4 A serological investigation done in Kanyakumari district of 
Tamil Nadu during 2003 dengue epidemic revealed DV-3 as the causative 
organism.9 
DV-3 isolated were reported from epidemics in Vellore in the year  1966 
and at Calcutta in the year 1983, Gwalior in 2003 and 2004, Tripur (TN) in 2010. 
A 2013 outbreak in Kolkata  involved three serotypes DV1, DV3  and DV4.5,8 
In Delhi uptil 2003, the predominant serotype was DV-2, but in the year 
2003 for the first point in time all four dengue virus serotypes were found to co-
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circulate in Delhi that altered it to a hyper endemic area and may be a reason 
for increased severity of DHF/ DSS.4 
EPIDEMIOLOGY: 
Agent 
The dengue viruses are members of the species Flavivirus and family 
Flaviviridae. These diminutive (50 nm) viruses enclose a single stranded RNA 
as genome.1,10 The virus is subclassified in four serotypes namely DEN-1, DEN-
2, DEN-3, DEN-4.1,10,11 All investigations  undertaken to this day show that the 
four serotypes of dengue virus core are phylogenetically diverse, and frequently 
to the same extent as different "species" of flaviviruses.11 The first dengue virus 
was taken from soldiers who became sick in Calcutta, New Guinea, and Hawaii. 
The virus is spherical and has an isometric core of 30-35 nm diameter. 
The nucleocapsid (or) core (c) protein is intricate with the single stranded RNA. 
This is enclosed by a lipid bilayer. which forms the covering and contains matrix 
(or) membrane (M) protein. The total span of the enveloped virus is 45-
60nm.1,13,14 
The Dengue virus genome is 11,644 nucleotides in extent and  has: 
1. Three structural protein genes which encodes the nucleocapsid core 
protein (C), a membrane – associated protein (M) and an envelope 
protein (E).1,13 
2. Seven non- structural protein (NS) genes – (NS1, NS2A, NS2B, NS3, 
NS4A, NS4B and NS5).1,13,16 Among the non structural protein, envelope 
glycoprotein NS1, is 45 kDa in size and  is connected with viral 
haemogglutination and neutralization activity.1 
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Functions of  structural proteins : 
C Protein : It is a 13 kDa protein. It contributes to group activation and is 
detected by compliment fixation test.  
E Protein : It is glycoprotein. It may help in anchoring of the virus to the host 
cell receptors. Antibody to E protein is protective.  
Pr M (M Protein): It has a molecular weight of 22 kDa. Its function is to 
stabilize polymerization of E protein. 
Functions of the Non –structural proteins : 
NS1 : 
 It is a membrane bound glycoprotein and is expressed  on virus infected 
cells. It has  replicative function. Antibodies to it are neither protective nor 
neutralizing.20,22 
NS3 : 
 It acts as a virus specific protease along with NS2A.20,22 
NS5 : 
 It is a virus polymerase.  
As mentioned before, 4 serotypes of dengue  exist. They have common 
antigens. They vary in their ability to cause disease.20,22 
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The Vector : 
 Aedes aegypti and Aedes albopictus are the two significant vectors of 
dengue1.  
Aedes (stegomyia) aegypti: 
 As the name suggests Aedes aegypti mosquito  has it’s origins in Africa, 
where it exists as a wild species procreating in forests free of humans. 
Subsequently the species adapted to the peridomestic environment. Slave trade 
and commerce during  17th to 19th centuries as well as World War II provided 
enough opportunities for the species to spread throughout the world. Other 
factors include rapid urbanization and population explosion, high scale of 
domestication and high attraction for human blood. Today Aedes aegypti is a 
cosmotropical species and it ranges between lattitudes 450N and 350S.1,14 
Aedes (stegomyia) albopictus : 
 Aedes albopictus is a species originating  in  Asia, native to South East 
Asia and islands of the Western Pacific and the Indian Ocean. Nevertheless 
during the last couple of decades the genus has extended  to continents like 
Africa, West Asia, Europe and the Americas. There is rising fear that Aedes 
albopictus can cause severe outbreaks of arboviral disease given that it is a 
proficient vector of atleast  22 arboviruses,especially dengue (all four serotypes)  
is more frequently transmitted by Aedes aegypti. 1,14 
 The common breeding sites for Aedes aegypti are domestic containers, 
ornamental containers, discarded receptacles, flower pots and roof gutters.13,14 
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The mosquito  breeds and thrives during rainy and post rain seasons. A 
higher atmospheric temperature results in proliferation of the Aedes 
mosquitoes, as well as high humidity.1 
Their morphology includes black body with white stripes. They bite 
predominantly during morning and late afternoon hours. They predominantly 
lives indoors and are endophagic.They feed mostly on human blood 
(anthrophilic). The lifespan is around 1-4 weeks and eggs are  not laid in 
clutches, which help in widespread dissemination and increased chance of 
survival and they withstand dessication for months. Transovarian transmission 
of the virus exists and this helps in maintenance during the interepidimic 
periods.1,14 
Aedes species other than aegypti and albopticus transmitting dengue are 
Aedes polyneinsis, Aedes cooti and Aedes cutellans hebrideus.13 
Host : 
Dengue viruses have evolved from mosquitoes, tailored to non-human 
primates and afterward to humans in an evolutionary course. 
The viremia amongst humans builds up to elevated titres, 2 days prior to 
the beginning of the fever and lasts 5-8 days following this through the febrile 
phase. During this phase the vector genus gets infected.1,16 
The spread of the virus happens through  the activities of the host (man) 
as the vector movement is very constrained.1,16 The susceptibily of humans 
depends upon the immune status and genetic predisposition1. Together 
monkeys and humans are amplifying hosts and the virus is sustained by 
mosquitos transovarially by means of eggs. 1 
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Transmission cycle: 
It occurs in three different cycles.  
1. Enzootic cycle :  
           A primitive sequence maintained by monkey- Aedes- monkey cycle  
is seen in South Asia and Africa. Virus is not pathogenic to the  monkeys 
and viremia persists for 2-3 days. All 4 serotypes have been taken from 
monkeys.1,16 
2. Epizootic cycle : 
The dengue virus crosses over to non-human primates from 
neighboring human epidemics  by vectors called bridge vectors. This was 
first observed  in Sri Lanka during 1986-1987 among toque macaques which 
was proved by serological studies. 1 
3. Epidemic cycle : 
This cycle  is maintained through human- Aedes – human cycle in 
episodic/ recurring epidemics. All serotypes move and leads to 
hyperendemicity. In general Aedes aegypti has little inclination to oral 
infection by dengue virus but it’s  really strong affinity towards human hosts 
(anthrophily), multiple feeding tendencies and extremely domesticated 
habitats make it an competent vector. 
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Transmission of DF/ DHF: 1,17 
Female Aedes mosquito bites human during viremic 
phase of illness  
 
Virus multiplies in the endothelial cell lining of the midgut of mosquito  
and  then enters into hemocoele 
 
 
 
 
 The existrinsic incubation period (ETP) extends from 8-12 days and 
mosquitos continue to be infected till the end of it’s life. The Intrinsic Incubation 
Period (IIP)  is from five to seven days.1,17 
The Human Phase ; 
 Following bite of an infected mosquito, virus multiplies in the local 
lymphnodes and in 2-3 days spreads to the blood and various tissues. Virus 
circulates in the blood for 5 days. It also replicates in the skin, splenic, lymphoid 
cells and macrophages.17 
Gains entry into salivary gland and 
infects humans through saliva  
 
Genital tract gets infected and virus  
enters fully developed eggs  during 
oviposition 
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Immunopathogenesis: 1, 16-29 
Dengue virus infection causes dengue fever (DF), dengue hemorrhagic 
fever (DHF) and dengue shock syndrome (DSS) , pathogenesis of which are 
not clearly unstated till date.16  Several hypothesis has been proposed 
regarding the access of virus into host cells and its replication and virulence.16,17 
Viral Entry and fusion with Target cells: 
 Entry of flaviviruses is helped  by numerous  activities taking place at the 
host cell.  The host cell has surface receptors and shows endocytic 
activity and triggers signals for infiltration.  
 Flaviruses are internalized into host cell by coated vesicles and 
transported into endosomes.  This process happens in an acidic Ph (6.5), 
optimally. 
 Monocyte – macrophages are the primary target cells for dengue viruses.  
 The virus E-proteins mediates the connection to cells, but the nature of 
host cell receptors remains obscure.  Probable receptors include Fc 
receptors, glycosaminoglycans (GAGS) and lipopolysaccharide binding 
CD14 – associated molecules.  
Dengue Virus Replication:18 
 Virus enters the host cell by receptor mediated endocytosis as 
described earlier.  
 Upon entry into host cell, endosomes are internalized and acidified, 
union of viral and vesicular membrane allows access of the 
nucleocapsid into the host cell cytoplasm and uncoating of the genome 
takes place.  
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 Translation of input strand occurs after which the virus switches from 
translation to synthesis of a negative – strand intermediate which 
becomes a template for the creation of multiple copies of positive – 
strand viral RNA (vRNA) ,subsequently produces high levels of  viral 
proteins. 
 This same process of translation produces multiple copies of structural 
protein capsid or core (C), premembrane (prM) and envelope (E) 
proteins.  
 Progeny virions are thus assembled which are  taken through the Golgi 
compartment and secreted.  
Molecular basis of Immunopathogenesis: 16, 20, 22, 23, 24, 25, 26 
Several hypothesis for the pathogenesis of dengue virus infection have 
been projected.  Among  the several hypothesis antibody dependent 
enhancement (ADE) of infection has long been understood to play a key role.  
 This was proved with sera got before infection from children who later 
developed DHF/DSS and were more likely to reveal ADE in vitro than those 
who had only DF. 
Effects of Dengue virus infection on Blood Cells:16 
(1) Aberrant Immune Activation during dengue virus infection: 
This theory was initially proved during a outbreak of dengue fever from 
November to December 1998 with serotype 3 in  the nation of Southern Taiwan. 
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(A) Inversion of CD4/CD8 ratio:  
 CD4+ are in excess than CD8+  T cells in peripheral blood of normal 
persons. In patients with DHF/DSS CD8+ cells exceed  that of CD4+ 
cells.  So that the ratio of CD4/CD8 cells declines to <1.  
 The occurrence of CD4/CD8 inversion was seen more in patients with 
DHF/DSS than in patients with DF. 
(B)  Atypical lymphocytosis and Bandemia: 
 The percentage of CD4dim and CD8dim monocytosis was higher or 
highest during day 6-7 in peripheral smear.  
 The immature neutrophil elevation (Bandemia) happened during days 
5-6 after the onset of fever. 
 Atypical lymphocytosis reached  the highest point on days 8-10 and 
then disappeared rapidly after day 12. 
 Early activation of mononuclear cells was established by expression of 
the early activation marker CD69 on day 4 after fever commencement. 
The appearance of atypical lymphocytes and active changes in the 
CD4/CD8 ratio suggest that aberrant immune activation does take place 
during dengue virus infection.  
2) Cytokine over production during Dengue virus Infection:  
 As mononuclear cells overactivation happens through acute dengue 
infection, it is anticipated that elevated levels of cytokines can be seen  in 
the serum  
 Pro inflammatory markers include: 
 
REVIEW OF LITERATURE 
 
19 | P a g e  
 
o T-cell activation markers – soluble CD4, soluble CD8, IL-2, soluble 
IL - 2 receptors and IFN-  
o Monokines - IFN-  , TNF  and GM-CSF.   
These markers were seen to be higher in DHF/DSS patients than in DF 
patients.  
 Elevated levels of inhibitory cytokines – IL-10, soluble receptors of 
sTNFR I, and sTNFR II  
 IL – 6 has twin roles as both a proinflammatory and an anti-inflammatory 
mediator.  Its kinete analysis showed disparity at different time points and 
in different persons.  
 These fluctuations in IL-6 imply that when a host responds to dengue 
virus infection through production of proinflammatory cytokines, at the 
same time there is also production of inhibitory cytokines to counter the 
inflammation.  
 Cytokines may cause cell activation synergistically or antagonistically, 
the overall effect will depend on the balance between various cytokine 
actions.  
Thrombocytopenia and Anti-platelet Antibodies:16,52,53 
 Thrombocytopenia is frequent in DF and almost always found in 
DHF/DSS.  The probable reasons of thrombocytopenia in dengue fever are: 
(1) Dengue virus – induced bone marrow suppression leading to low platelet 
synthesis and  thrombocytopenia  
(2) Platelet destruction induced by DV antigen attached to human platelets 
without immune mediated reaction.  
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(3) Anti-platelet autoantibodies (predominantly IgM class) induced platelet 
lysis and it also inhibits ADP-induced platelet aggregation.  The affinity 
towards these auto antibodies is enhanced in secondary dengue 
infection.  
So far this hypothesis holds good and has enough animal models 
and human studies.52,53,66 
(4) A modulation of endothelial cells by the infection of DV to the cell, was 
suggested as one of the cause of thrombocytopenia.52  
Dengue Virus – Induced Vasculopathy:16,19 
 The most typical feature of DHF/DSS and the best pointer of disease 
severity is plasma leakage 
 Plasma leakage is caused by a faulty increase in capillary permeability and 
manifests as combination of hemoconcentration, pleural effusion, or ascites.  
 Plasma leakage occurs systemically, moving ahead quickly and usually 
resolves in 1-2days in patients who receive sufficient fluid resuscitation.   
 Although perivascular oedema is apparent no destruction of vascular 
endothelial cells are usually obvious. 
 Functional modification of endothelial cells is most likely caused by effects of 
cytokine or mediator release such as IL-6, IL-8 and RANTES. 
 In vivo studies have demonstrated destruction and apoptosis of endothelial 
cells  especially by certain strains of DENV-2 (Strain PL 0046) 
 Dengue virus infected endothelial cells are able of activating complement 
and expression of adhesion molecules such as ICAM-1. The expression of 
ICAM-1 along with the production of chemokines IL - 8 and RANTES 
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increases the adherence of  PMN and mononuclear cells to vascular 
endothelium and increase in vascular permeability and thrombomodulin 
release.  
 Thrombomodulin is a marker of endothelial damage and its levels were 
found to high in patients with DHF/DSS indicative of endothelial structural 
damage.  
 It is concluded that direct viral cytopathic effects, immune mediated 
endothelial damage by leukocyte recruitment and anti-dengue antibodies 
can cause structural injury to infected endothelial cells.  
As endothelium plays a central role in maintaining 
hemostasis,endothelial damage may result in procoagulant / anticoagulant 
imbalance, sequestration of platelets by  the activated endothelial cells 
contributing to thrombocytopenia will increase bleeding tendencies apart from 
plasma leakage  
Dengue Virus – Induced coagulopathy:16,22,23,24,26,27,28 
 The pathogenesis of bleeding in DHF is unclear even though well 
recognized coagulation disturbances exist.  
 Clinical manifestation ranges from a positive torniquet test, 
ecchymoses, skin petechiae to epistaxis and gum bleeding to severe 
gastrointestinal hemorrhage.25 
 Hemorrhage results from two mechanisms  
(i) Severe thrombocytopenia and associated platelet dysfunction 
and endothelial dysfunction 
(ii) Coagulopathy including DIC. 
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(iii) Hemostasis is maintained by the equilibrium between 
coagulation and fibrinolysis.  
 Coagulation system - consists of intrinsic as well as extrinsic 
pathways          
Activation 
               Thrombin formation 
Converts 
                Fibrinogen – Fibrin  
    Leads to  
                               Formation of thrombus 
 Fibrinolytic system  
(facilitates fibrinolysis – clot lysis)  
 
Plasminogen (proenzyeme)  
 
Activated by various types of  
Plasminogen activators  
(Principal endogenous activator is tissue – type plasminogen activator 
(tPA)) 
                           Conversion of plasminogen to  
 
         Active plasmin enzyme 
                           Breaks down 
 
  Fibrin to fibrin degradation products (FDP)  
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 tPA is inhibited by plasminogen activator, inhibits (PAI-1) which is 
synthesised by liver, platelets and endothelium.  
 Coagulation activation  
                             Triggers  
Secondary activation of fibrinolysis  
                             Rapidly shut down by  
Discharge of large amount of PAI – 1  
 
 In acute dengue infection, thrombocytopenia and altered liver 
functions leads to reduced PAI-1 secretion and in turn leads to 
bleeding disorder.  
 In addition there is defect in intrinsic pathway of coagulation 
leading to a prolonged aPTT.  
 Summarising the coagulation disorder  in DHF/DSS, factors which 
leads to a greater risk of hemorrhagic tendencies are 
    (i)  Thrombocytopenia   
     (ii) Endothelial Dysfunction  
                    (iii) Raised tPA activity 
                    (iv) Subnormal PAI-1 activity 
                    (v) Prolonged aPTT.  
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Pathogenesis of liver cell Dysfunction:16,29,61 
 The clinical confirmation of liver involvement in dengue infections include 
the presence of hepatomegaly and augmented levels of liver enzymes.61 
 Several studies have found the elevation of aminotransferase to the tune 
of >90% (AST) and >80% (ALT) in cases of DF, DHF/DSS. 
 The elevation of transaminases tend to be higher in patients with 
DHF/DSS than in DF.16,61 
 The levels usually return to normal range by 14-21 days after infection.61 
 Fulminant heptitis and hepatic failure have been recorded in patients with 
DHF/DSS and carries a poor prognosis.29 
 There is no evidence chronic liver cell failure in patients with DF/DHF.61 
 The level of AST appears to get elevated more than ALT, which is vice 
versa in other viral hepatits.61 
 The elevated AST levels usually returns to normal more quickly than ALT 
levels this may be due to shorter half-life of AST than ALT.61,29 
 Histological changes in hepatitis associated with DF includes 
steatosis,microvesicular, hepatocellular necrosis, Kupffer cell hyperplasia 
and destruction, Councilman bodies and cellular infiltrates at the portal 
tract.  
 Hepatocellular necrosis in DF usually affect the midzonal and sometimes 
the centerilobular areas. The cause for this phenomenon is that cells in 
midzonal area are more susceptible to anoxia or to products of immune 
response (Cytokines and chemokines) or dengue virus preferentially 
infects cells in this zone.61,16 
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 Inflammatory cell that typically infiltrates the liver during DF are 
mononuclear cells.  
 The Dengue virus has the capability to infect both hepatocytes as well as 
Kupffer cells but replication occurs efficiently in hepatocytes only.  
 The destruction of hepatocytes in either due to direct involvement of 
dengue viruses leading to apoptosis or may be immune mediated 
destruction.16,61 
Clinical Manifestation: 
Dengue virus illness may be asymptomatic or may lead to 
undifferentiated febrile sickness, dengue fever (DF) or dengue hemorrhagic 
Fever (DHF) plus dengue shock syndrome (DSS). 1,7 
Infection with one dengue virus serotype gives life long immunity to that 
similar serotype, but there is only  a short period  of cross protection for the 
other  different serotypes. The clinical symptoms depends on the virus strain 
and host factors like age, immune status etc.1 
Undifferentiated fever : 
Primary dengue infection possibly will present with a  fever 
indistinguishable from other viral syndromes with accompanying maculopapular 
rash and respiratory or gastro intestinal symptoms. 1 
Dengue fever (DF) : 
It is seen most commonly in older children, teenagers and grownups. It 
presents as illness, with sometimes with biphasic fever accompanied with 
headache, myalgias, arthralgias, rashes, thrombocytopenia and leucopenia The 
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severe manifestation of the above mentioned symptoms have given rise to the 
terminology "break – bone fever". 1,3,7 
The intrinsic incubation perioid is usually 4-6 days with a range of 3-14 
days. The temperature is usually between 390C-400C and lasts for 5-7 days. 
This is accompanied by myalgias, arthalgias, retro orbital pain, photophobia. 
Other symptoms includes nausea, anorexia, constipation, diarrhoea, abdominal 
pain,sore throat and depression. The symptoms may continue from quite a few 
days to weeks.1,3,7 
The rash manifests as diffuse flushing or fleeting eruptions in the first 2-3 
days over face, neck and chest. A evident rash may be maculopapular or 
rubelliform, appears between 3-4 days and by the end of febrile phase or right 
away after defervesence .This widespread rash fades and localized clusters of 
petechiae become visible over the dorsum of the feet, over  the legs , on the 
hands and arms.1,7 
The relative period and relentlessness of  the illness varies between 
individuals and between one epidemic to another. Convalescence may be of 
short duration but sometimes prolonged and extends for several weeks and is 
followed by marked asthenia and depression. Bradycardia is frequent during 
this period. Hemorrhagic manifestations are unusual in dengue fever(DF).1,3,7 
Dengue Hemorrhagic fever and Dengue shock syndrome : 
Dengue hemorrhagic fever (DHF) is for the most part frequent in children 
less than 15 years old in hyperendemic areas associated with repetitive dengue 
infection.1Abnormal  hemostasis and plasma leakage are the hallmarks of DHF. 
Thrombocytopenia and increasing hematocrit/ hemoconcentration are invariable 
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findings prior to the subsidence of fever/ onset of shock. It is frequently 
associated with secondary dengue infection, but primary infection with DEN-1, 
and DEN-3 as well as infants can manifest this from of dengue syndrome, 
without prior infection. 1,3,7,19 
The initial clinical manifestation of DHF/ DSS resembles symptoms of 
DF. Illness begins with high fever which lasts for 2-8 days before diminishing to 
normal or sub normal levels. Constitutional symptoms include anorexia, 
headache, muscle or joint pains and throat pain, with injected pharynx.1,7,19 
Epigastric uneasiness, tenderness at the right costal margin and 
generalised abdominal aches are frequent. A positive torniquet test ( 10 spots/ 
square inch), the most frequent hemorrhagic occurrence, could be seen in the 
early febrile phase.1,7,19 
 Rash as described in dengue fever may develop during febrile phase and 
during convalescence.  
 Bleeding in the form of epistaxis and bleeding gums are less frequent. 
Mild gastro intestinal hemorrhage is infrequently seen. 
 Liver is typically palpable during premature febrile stage, varying from 
just palpable to 2-4 cms beneath  the right costal margin. Hepatomegaly is seen 
more frequently in shock cases. Splenomegaly is observed more frequently in 
infants under twelve months.1,19 
 The grave phase of DHF i.e. the phase of plasma leakage, begins just 
about the shift from  febrile to the afebrile phase .Confirmation of plasma 
leakage includes pleural effusion and ascites. Gall bladder oedema has been 
seen to herald plasma leakage.1,3,7,19 
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 In mild cases of DHF, all signs and symptoms subside after the fever 
abates. Patient more often than not recover either unexpectedly or after fluid 
and electrolyte treatment.1,7,19 
Dengue shock syndrome : 
 In moderate to severe cases of D.H.F the patients state deteriorates a 
few days after the commencement of fever. There are warning signs such as 
persistent vomiting, abdominal aches, reduced oral ingestion,lassitude and 
irritability.1,2,7,25 
Hypotension and Oliguria : 
 By the time or shortly after the febrile phase ends there are evidence of 
circulatory collapse.1,7,25 The skin becomes cold, blemished and congested, 
circum- oral cyanosis is often seen. The pulse becomes feeble and fast.1,7,25 
 The shock is manifested  by a weak and rapid pulse with the reduction of 
pulse pressure (  20mm Hg), an augmented diastolic blood pressure (or) 
hypotension. Signs of decreased  tissue perfusion  capillary refill1) <3 seconds 
2)Cool, damp skin and3) agitation. If appropriate intervention is not done patient 
may deteriorate into a profound shock with pulse and blood pressure becoming 
unnoticeable (grade 4 DHF) .Shock is reversible if  adequate treatments with 
volume  replacement and fluid resuscitation is given, otherwise the patient may 
die within 12-24 hours. 1,7,25 
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Criteria for clinical Diagnosis of DHF/ DSS:1,2 
1. Fever of  high grade / lasting for 2-7 days.  
2. Any of the subsequent hemorrhagic manifestations – positive tourniquet 
test (the commonest), petechiae,purpura, ecchymosis, epistaxis, 
bleeding gums and hematemesis and /or melena. 
3. Shock,characterised by tachycardia, low  tissue perfusion with feeble 
pulse and lessened pulse pressure (20mm Hg or less) or hypotension 
with presence of cool, sweaty skin and / or agitation. 
4. Enlargement of liver (is seen) at some point of the disease in 90%-98% 
of kids 
Clinical Laboratory Findings in Dengue fever (DF):1 
 Total WBC count is more often than not normal at the commencement of 
fever followed by leucopenia.  
 Platelet count is frequently normal. Mild thrombocytopenia in the range of 
1,00,000 to 1,50,000 cells/mm3 is common.  Around 50% of  patients with 
DF will have platelet count of <1,00,000 cells/mm3 .Severe 
thrombocytopenia (<50,000 cells/mm3) is usually rare.  
 Mild elevation of hematocrit (~10%) may be found as a consequence of 
dehydration.  
 Biochemistry tests especially liver enzymes (AST,ALT) may be slightly 
elevated.  
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Clinical Laboratory findings of DHF:1 
 WBC count : 
It can be normal with predominant neutrophils in the early febrile 
phase. Then it may drop reaching a lowest point towards the end of febrile 
phase. A total WBC count of   5,000cells / mm3 and a ratio of neutrophils to 
lymphocyte (neutrophils < lymphocytes) is helpful to foresee the critical 
period of plasma leakage. This result precedes thrombocytopenia or rising 
hematocrit.  A relative lymphocytosis with increased atypical lymphocytosis 
is frequently observed by the end of febrile phase.  
 Platelet count: 
Platelet counts are normal during the beginning of the febrile stage.  A 
sudden fall in platelet count below 1 lakh occurs by the ending of the febrile 
phase.  The level of platelet count correlates with the severity of DHF.  
 Hematocrit: 
It may be normal during early febrile stage.  A trivial increase may be 
because of  high fever and dehydration.  Hemoconcentration or rising 
hematocrit by 20% from the baseline is a objective evidence of plasma 
leakage. 
  Activated partial thromboplastin time (aPTT) and prothrombin time (PT) are 
lengthened in about one third and half of DHF cases respectively.  Thrombin 
time is delayed in severe cases.  
 Other findings: 
- Hypoproteinemia / hypoalbuminemia as outcome of plasma leakage  
- Hyponatremia 
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- Elevated ALT – AST usually at levels   200 IU/L with a ratio of AST:ALT 
>2. 
- Hypocalcemia is usually seen in most cases of DHF, the level is lower in 
Grade 3 and 4.  
- Metabolic acidosis is often found in patients with prolonged shock.  
- Blood urea and creatinine is also increased  in patients with prolonged 
shock. 
Thrombocytopenia(100,000 cells/mm3 or less) and hemoconcentration or 
a increasing hematocrit   20% from the usual values are adequate to establish 
a clinical conclusion of DHF. In cases with shock, a elevated hematocrit and 
marked thrombocytopenia hold up the diagnosis of DSS.1,2 
Laboratory Diagnosis : 
 Swift and precise diagnosis is of vital importance for 1,31 
i) Epidemiolgical observation  
ii) Clinical managing  
iii) Vaccine trials 
iv) Research 
 Early diagnosis is of paramount importance in successful management 
of dengue fever and identifying circulating serotypes/ genotypes during 
interepidemic phase for use in forecasting possible outbreaks.32 
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Blood collection in Tubes or Vials :1,32,35 
 Withdraw 2-10 ml of venous blood with aseptic precaution.  
 Labelling should include patient's name, identification number and data 
of collection. 
 Use vaccum tubes or disinfected vials with screw caps and gasket. 
 In anticipated delay of  > 24 hours separate the serum and store frozen.  
Specimens : Collection, storage and shipment:1,32 
 Blood is collected as paired specimens. 
 Collection specimens are divided according to the different time intervals 
they  are acquired. 
i) Acute phase specimen (S1) : 
  They are collected as soon as possible after the onset of illness 
(0-5 days of onset), stored at -700C, and transported in dry ice 
ii) Convalescent phase specimen (S2) 
  They are obtained during release from hospital (or) in the 
occurrence of a fatal outcome. 
iii) Late Convalescent phase specimen(S3) : 
  They are collected 7-22 days after the acute  phase serum was 
drawn.  Both S2 and S3 are stored at minus 200C and shipment done in 
Frozen or ambient state.  
iv) Tissue sample:  
  They are collected as soon as possible after death , stored at 
minus 700C or in formalin, transported in dry ice. 
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Shiping done with wet ice for blood and dry ice in case of serum.  Shiping 
should stick on to national international procedures for transportation of 
infectious substances 
Diagnostic Tests :1 
 Virus Isolation – Serotypic/ genotypic classification  
 Virus Nucleic acid finding 
 Virus antigen recognition  
 Immunological response based  tests – IgM and IgG antibody assays  
 Study for hematological criteria 
Diagnostic test and phases of disease: 1,31,32 
 Viremia 
  Typically occurs 2-3 days prior to onset of fever to 7 days of illness. 
During this phase dengue virus, nucleic acid and viral antigens (NS1) 
can be detected.  
 Antibody response  
i) IgM antibody – 3-5 days of onset of illness, rises upto 2 weeks to 
imperceptible  levels after 2 or 3 months  
ii) IgG antibody – demonstrable by end  of week and remains elevated 
for many years  
Diagnostic methods for Detection of Dengue Infection 1,35 
 Dengue  early stages of disease, virus segregation, viral nucleic acid or 
antigen discovery can be used and at the end of acute stage immunological 
tests are the preferred method for analysis.  
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A) Segregation of virus :35 
 Ideal sample collected within six days of illness 
 Preferred specimens – Acute phase serum, plasma, washed buffy coat, 
autopsy tissues like (liver specimen, lymph nodes ,thymus) ,live 
mosquitoes  
 Mosquito cells culture followed by live mosquito innoculation are the 
most preferred methods .Innoculation of suckling mice if the former 
methods are not available. 
 Mosquito cell lines C6/36 or AP61 are the host cells of preference for 
segregation by dengue viruses.  
 Preferred : Mosquitoes include in order of sensitivity : Toxorhynchites 
amboinensis, Ae.aegypti and Ae.albopictus 
B. Viral Nucleic Acid Detection:35 
 The primary investigation used is RT- PCR. The sensitivity for the 
method is 80-100%. RNA is heat labile and therefore specimens should be 
handled carefully. Methods comprise: 
 Reverse transcriptase – polymerase chain reaction (RT-PCR) 
 Nested RT- PCR 
 One Step multiplex RT- PCR 
 Real time RT- PCR 
 Isothermal amplification method  
 Loop mediated  amplification (LAMP) PCR  
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 These tests need a BSL 2 lab with gear for molecular biology and trained 
professionals. The newer modalities can be used to identify  different serotypes, 
early detection of infection and include high sensitivity and specificity. 
c) Viral Antigen Detection 1,37,38,39 
 Out of the dengue non- structural proteins, the NS1 antigen detection 
has revolutionalised early diagnosis of dengue fever1. 
 Commercial availability of NS1 detection kits are there scince 2002.38 
 NS1 antigen is a highly preserved glycoprotein, produced in both 
membrane bound and secretary forms, is abundant in the serum of 
patients during early stage of DEN-V infections. 1,38 
 NS1 antigen shows up as early as day 1 after the onset of fever and 
persists upto 9 days.1,38,44 
 In secondary dengue infections antibodies clear NS1 from circulation 
within 5-7days. 37,39,45 
 Detection of NS1 antigen by ELISA method is preferable.1,45 
 Immuno enzymes and immunochromatographic techniques (i.e. rapid 
tests) are also available at present. 1,38 
Immunological Response and Serological Tests :1,37 
 Five fundamental tests are used for the diagnosis of dengue infections 
they are : 
i) Hemagglutination – inhibition (HI).  
ii) Complement fixation (CF) 
iii) Neutralization test (NT) 
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iv) IgM capture enzyme linked immunosorbent assay (MAC- ELISA 
Indirect IgG ELISA) 
 For diagnostics other than those that detect IgM,unequivocal 
corroboration depends on a noteworthy (four fold or greater) rise in specific 
antibodies amid acute phase and convalescent- phase serum samples. 
1. IgM antibody capture Enzyme – linked Immunosorbent assay (MAC 
ELISA)1,31,35,41,42 
 MAC ELISA is a simple and rapid test which has become extensively 
used in the last few years.1 
 It is based on the  detection of  the dengue specific IgM antibodies in the 
test serum by capturing them out of solution using anti-human IgM that was 
beforehand bound to the solid phase. 
 Anti Dengue IgM antibody is usually detectable by day 5 of the illness, a 
little earlier than IgG.  
 IgM antibody titres are significantly higher in primary than secondary  
 Levels peak at around 2 weeks after the start of symptoms and in most 
patients it decreases to an untraceable levels by 60 days. It might persist  
upto 90 days.  
 A positive IgM MAC – ELISA is suggestion of recent dengue infection. 
 It is particularly helpful for hospitalized patients who are usually admitted 
at a last phase of illness. 
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IgG ELISA :
1,31,35 
 It is an easy to perform test and primarily used it differentiate between 
primary and secondary dengue infection. 
 IgG ELISA is extremely non- specific in terms of cross reactivity among 
other flavi viruses.  
 IgG antibodies starts rising at the end of first week and remains  elevated 
for many years. 
IgM/ IgGRatios :
1,31,35 
 It is used to differentiate between primary and secondary infection.  
 Primary infection is defined by a capture IgM/ IgG ratio > 1.2  
 Secondary infection if the ratio is < 1.2  
Hemagglutination Inhibition Test (HI) :1,31,35 
 It is sensitive, easy to perform and was used previously for routine  
serological diagnosis of dengue infection. 
 HI antibodies persist for > 50 years and are best for sero- epidemiologic 
studies. 
 Main drawback is that the test lacks specificity. 
Complement fixation Test  (CFT) :1,31,35 
 CFT is used to diagnose current infection. 
 Its use is restricted because it is complex to perform and requires highly 
skilled personnel. 
 
 
 
REVIEW OF LITERATURE 
 
38 | P a g e  
 
Neutralisation Test (NT) :1,31,35 
 It is the most sensitive and specific serological test.  
 The disadvantages are that this test is expensive, time consuming and 
needs expertise.  
 It finds immense use in the making of vaccines and in their efficacy trials. 
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MANAGEMENT  
There is no specific therapeutic agent for dengue virus infection.  High 
dose of steroids have no role in recovery. There is no benefit of using I.V. 
immunoglobulin.  There is no antiviral drug specific to its treatment. 
Management of dengue fever:1,7 
Symptomatic treatment with bed rest, antipyretics and analgesics.Aspirin 
is avoided as it may aggravate gastritis or bleeding tendencies.  In children 
Reye's syndrome may be a grave complication.  Antibiotics do not play a role 
here. 
 Oral rehydration is essential. ORS (oral rehydration solution) is 
suggested for patients with excess sweating, vomiting or diarrhoea to avert 
dehydration. 
 Food is given according to appetite following recovery from the fever. 
The patient is monitored for 2 days for shock which is a complication during this 
period.   
Management of dengue haemorrhagic fever:1,7 
 Prognosis depends upon early recognition of plasma leakage which can 
be assessed by rise in hematocrit level.  Repeated monitoring may be required. 
Patient should be admitted when rise in hematocrit is 20% or more, single 
hematocrit is more than 40% ,platelet count of 50,000/mm3 or less, presence of 
unprompted haemorrhage or signs and symptoms of shock or oliguria or 
circumoral cyanosis.  Treatment should include antipyretics like paracetamol. 
Oral fluids are to be given to avoid dehydration.  IV fluids should be given along 
with constant monitoring of haematocrit level and regular estimation of vital 
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signs like urine output to circumvent over infusion  and hence circulatory 
overload.  To prevent fluid overload, fluid therapy is stopped when hematocrit 
drops to approximately 40% and clinical signs and urine output improves.  
Management of dengue shock syndrome:1,7 
 Here volume replacement by intravenous fluid administration helps to 
expand the plasma volume.  Close observation with constant monitoring of vital 
signs, urine output and hematocrit is important. 
 FFP or concentrated platelet transfusion can be initiated when 
disseminated intravascular coagulation leads to substantial bleeding.  
Theoretically the thrombocytopenia is a risk issue for haemorrhage. The 
threshold for prophylactic platelet transfusion is 10,000/mm3 in non dengue 
cases.  It has been recommended that since there is no definite therapy for 
DHF/DSS, patients bleeding tendency and a platelet count of less than 20,000 – 
25,000 / mm3-may be empirically transfused platelets.  If clinically indicated fluid 
electrolyte replacement should be done.  
Platelet Transfusion in Dengue fever:1,2,46,47,48,49 
 Thrombocytopenia is one of the important finding in dengue fever.  It is 
almost always associated with dengue hemorrhagic fever.  The medical 
fraternity internationally recognizes the role of platelet transfusion in the 
management of hospitalised dengue patients,  but the precise indications and 
situations in which transfusion is done may vary.  There is always a  dilemma 
regarding platelet  transfusion in a non - haemorrhagic patients  with dengue 
fever.  A platelet count of <1,00,000 cells/cu.mm with evidence of bleeding is 
almost always an indication for platelet  transfusion in a patient with dengue 
 
REVIEW OF LITERATURE 
 
41 | P a g e  
 
fever.  There are no clear cut guidelines regarding  platelet transfusion in our 
scenarios.  
 In general a platelet count of <50,000cells / cu.mm is associated with 
minor risk of any form of bleed, and the risk increases if the platelet count drops 
by 10,000-20,000 cells /cu.mm and the risk of major bleeding including hollow 
viscous bleed is substantially more.  The risk of bleeding is more when 
thrombocytopenia is associated with coexsisting coagulopathies, liver disease, 
platelet inhibiting drugs and infection.  The minimum threshold for platelet 
transfusion is <10,000 cells / cu.mm in otherwise stable patients as a general 
rule.   
 As it is understood not only the quantity of platelet is altered in DF, also 
the quantity i.e. the functional part is also affected they may lead to an 
increased risk for haemorrhage in patients with dengue fever.  Many studies 
have shown including the WHO guidelines for prevention and control of DF that 
the level of thrombocytopenia and risk of hemorrhage in DF has poor 
correlation, but some studies have enough evidence that the risk of hemorrhage 
in substantially raised with the level of thrombocytopenia, especially if the 
platelet count drops below 20,000 cells / cumm. 
Factors affecting the prognosis of Dengue fever :1 
1. Existence of enhancing and non-neutralizing antibodies increases the 
severity. 
2. Age:Suceptibility of DHF / DSS falls considerably after age of 12 yrs. 
3. Sex: Females are very often affected than males 
4. Face: Caucasians are more often affected than blacks 
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5. Sequence of infection: Serotype 1 followed by Serotype 2 infection 
seems to be more unsafe than Serotype 4 followed by Serotype 2  
6. Infecting serotype : Type 2 is in fact more perilous than the other 
serotypes  
Dengue vaccines:1-3,7 
 The vaccine for dengue is in the process of development and trials.  No 
ideal vaccine has been produced.  Any vaccine synthesized must be tetravalent 
as preexisting heterotypic dengue virus antibody becomes a risk factor for DHF.  
 The different types of vaccines are 
1. Live attenuated dengue vaccine 
2. Chimeric dengue vaccine  
These are synthesized using recombinant DNA technology. Here a 
chimera is created in which the structured protein genes for target antigens of a 
virus was replaced by equivalent genes of another virus.  Hence a chimera was 
created with required attenuation phenotypes and expression of target antigen. 
a. Chimeric yellow fever/dengue virus (ChimeriVax-Den) was 
developed.  The vaccine expressed the premembrane (PrM) and  E 
genes for dengue virus 2 in an yellow fever virus (YFV – 17D) genetic 
background.  
b. ChimeriVax – DEN, was constructed and represented DV serotype 1 
to 4 by electroporation of vero cells with RNA transcripts made from 
viral cDNA.  
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DNA Dengue vaccines:1,2,3 
 Here PrM, the genes of dengue virus – 2 were cloned into different 
eukaryotic plasmid expression vectors.  The vaccine obtained was tested by 
introducing into BALB/c mice intradermally.Rhesus macaques were also used.   
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Case studies in Dengue fever : 
Bandyopadhyay B,Bhattacharya I,Adhikary S,Konar J,Dawar N et.al.55 in 
their study titled "A comprehensive study on the 2012 Dengue fever outbreak in 
Kolkata, India" done at the Calcutta School of Tropical Medicine selected 62 
cases of clinically suggestive dengue fever to evaluate the performance of the 
newly introduced dengue NS1 antigen detection test (Pan Bio – Australia NS1 
ELISA Kit) who reported early just after the onset of fever and were followed up 
to 14 days of illness.  Out of the 62, 38 of the patients tested positive for NS1 
antigen and 24 cases were found negative for NS1 antigen.  Out of the NS1 
positive patients, 24 were also found to be positive for dengue IgM antibodies 
and rest 14 of the were IgM negative. The possible causes include false positive 
NS1 antigen test or may be secondary dengue infection where the IgM antibody 
titre tend to be undetectable. Out of the 24 negative cases 6 of them 
subsequently become positive for IgM ELISA during follow-up. This shows that 
NS1 antigen positivity should be correlated clinically for reasonable accurate 
diagnosis of DF.  
 Hati AK56 in his work quoted “Studies on Dengue and Dengue 
Hemorrhagic fever (DHF) in West Bengal state, India” at a tertiary care hospital 
in Kolkata, screened a total of 874 patients with acute febrile illness during 
August to November 2005 dengue epidemic were quantitatively analysed for 
dengue IgG and IgM antibodies using the FVD Microwell ELISA dengue fever 
test  kit found that 52.6% had only IgG antibodies positivity, followed by 8.9% 
only had IgM antibodies positive, followed by 16.8% had both IgG and IgM 
positivity. 21.6% tested negative for both IgG and IgM ELISA.  Out of these 10% 
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developed DHF and the case fatality rate was 8.5% among patients with DHF 
the out break was caused by serotype DEN – 3.  
 Tewari KN,Tuli NR,Devgun SC57 in their retrospective study titled“Clinical 
profile of dengue fever and use of platelets in four tertiary fever hospitals of 
Delhi in the year 2009"  obtained data by observing the formats and case 
records from 3 private multispecialty nursing areas within Delhi.  A Total of  230 
seropositive cases out of 426 patients of Dengue fever / Dengue hemorrhagic 
fever admitted between July and December of 2009 were randomly selected 
from MRDs of these hospitals. The inclusion criteria were seropositivity  for 
DF/DHF by NCDC. Exclusion criteria were sero negativity and  those cases 
where consent was denied by the hospital authorities. The age of these patients 
who were included in this study group were between 6 years and 82 years.  The  
mean age for males was 30.4 years and 39.0 years for females. Out of the 230 
cases studied, 163 (70.8%) had dengue fever (DF) and 67 cases had DHF.  
Fever was almost always present in all cases who got admitted.  Other 
symptoms frequently encountered were vomiting (36%), pain abdomen (34%), 
headache (27%), myalgia (24%), nausea (19%), common bleeding 
manifestations were epistaxis, haematemesis and melena.  In patients with 
DHF, hepatosplenomegaly with pleural effusion and ascites were the 
commonest finding (70.5%).  Out of the DHF group, 3 patients (4.4%) 
manifested DHF class III (DSS).  Platelet transfusion was done in 80 cases 
(48.7%) of DF group and 50 cases (73.5%) of  DHF.  141 patients (82.6%) of 
DF patients had platelet count of 1,00,000. Minimum platelet count observed 
was 2,000 followed by 3,000 in cases of DF who didn't have any serious 
bleeding manifestations. Minimum units of platelets transfused is one and 
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maximum was 16 units with an average of 4.23 units.  Platelet transfusions 
were not done as per international guidelines but was rather administered as 
per the severity of thrombocytopenia and in the anticipation of impending bleed.  
The positive outcome regarding platelet transfusion is that the average hospital 
stay for patients who received were 4.9 days compared to those without 
transfusion (5.3 days) with a significant p value (p = 0.0416).  A total of 2 deaths 
were encountered in DHF group.  
 Raju  BJ,Rajaram G58 in their study titled "Prevalence of Dengue fever 
and Dengue Hemorrhagic Fever in Government General Hospital,Tirupathi" 
which was done at Department of Microbiology, S.V.Medical College, Tirupathi 
over a period between August 2007 to July 2008, screened a total of 200 cases 
who got admitted with clinical features suggestive of DF by testing their serum 
for dengue IgM antibodies using IgM capture ELISA test.  Out of 200 patients 
121 were male and 79 were females.  Out of the 200 cases, 75 (37.5%) tested 
positive for dengue IgM ELISA.  The commonest presenting symptoms are as 
follows fever (100%), headache (92%), myalgias/arthalgias (85.5%), nausea 
and vomiting  (84.5), Pedal oedema (75.5%), skin rash (69.5%), pain abdomen 
(55.0%) conjunctival congestion (41.0%), Hepatosplenomegaly (30.0%), altered 
sensorium (28.5%), Retrobulbar pain (26.5%), Ascites (21.5%), Hemorrhagic 
manifestations (11.0%)   
 Khan AK, Sitwat A, Masood N, Solangi NM, Shaikh TZ et al69 in their 
retrospective study of patients with acute febrile illness, concluded that 50% of 
patients presented with typical features of dengue fever were aged between 13-
70 years.  Only 40% were dengue proven. Out of these 18 had DF and 2 of 
them had DHF.  Typical clinical features like fever with chills in 16 (80%), 
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Myalgia (10%), headache in 10 (50%), vomiting in 12 (60%), , pharyngitis in 7 
(35%), rash in 5 (25%) and bleeding manifestations in 5% patients.  
 Lt.Col.Banerjee M, Lt.Col.Chatterjee J, Lt Col Choudhary GS, Col 
Srinivas V, Brig.Katari V.K 63 in their observation of 50 clinically inspected 
dengue cases concluded that 27 cases (54%) were confirmed positive by IgM 
antibody assay (ELISA). Commonest clinical features were fever with rash 
(85%) retroorbital headache (63%) myalgia (81%), hepatomegaly (15%) and 
hepatosplenomegaly (7%), Hemoglobin < 9.5gm% (11%), thrombocytopenia of 
<1,000,00 cells/cumm in 19%, leucopenia was not observed in this study.  
 Jain A,  Shah A,  Patel P,  Desai M, Somani S,  Parikh P et.al65 in their 
study of 56 patients with dengue fever mostly among medical professionals in a 
tertiary care hospital in Ahmedabad has found fever followed by myalgia as 
commonest symptoms.  the most common predictor of severity were raised 
hematocrit of >40% and a low platelet count of <50,000 cells/cu.mm. The 
mortality rate was 1.7% 
 Lin SF, Liu HW, Chang CS et al67 in their study of patients with dengue 
fever in  a Chinese hospital observed that leucopenia was present in 76% of 
cases and a thrombocytopenia of <1,00,000cells /cu.mm in 54% of the cases.  
Leucocyte count normalised at the 5th – 6th day after the onset of fever and 
thrombocytes reached nadir by 5th – 7th day after fever onset. Bone marrow 
studies in these patients revealed mild hypocellularity in the acute stages and 
normocellularity during the convalescent stage i.e. after I week post febrile 
phase.  
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 Turbadkar D, Ramachandran A, Mathur M et al68 in their retrospective 
study named "Laboratory and clinical profile of dengue: A study form Mumbai". 
did  a screening of 3,677 clinically suspected cases of dengue fever at a tertiary 
care hospital by rapid test for antibodies against dengue. Out of these 503 
(13.67%) sample tested positive which included positivity for IgM antibodies 
alone 288 (57.25%) (or) for both IgM and IgG antibodies  107 (21.27%).  Those 
cases with IgG alone being positive were not taken into consideration as it 
suggested a remote infection .Only 212 out of 503 cases tested positive by IgM 
ELISA method the period of study was between January 2004 to November 
2007.  The peak incidence of cases on monthly basis was between July and 
November that suggests later part of monsoon as well as the post-monsoon 
period. Fever was the major clinical symptom (100%), followed by myalgia 
(25.0%) and headache (13.9%), thrombocytopenia (platelet counts <75,000 
cells/cu.mm) were noted in 386 cases (76.74%), 68 cases (17.6%) has counts 
below 20,000 cells/cu.mm, 241 (62.4%) had counts between >20,000 –
50,000cells / cu.mm and 77 (19.9%) had counts between 50,000 – 75,000 
cells/cu.mm. 
       Mandal SK, Ganguly J, Sil K, Chatterjee S,  Chatterjee K, Sarkar P et al 70 
in their study titled "Clinical Profiles of Dengue fever in a teaching Hospital of 
Eastern India".  This study was conducted in a territory care hospital. A total of 
74 MAC ELISA positive dengue cases were studied.  The most common clinical 
manifestation was fever (100%) followed by headache (62.16%).  Atypical 
manifestation like transaminitis and neurological manifestation were present in 
83.83% and 11.0% cases respectively.  
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 Fatima S, Abeddin MA, Firdous F 71 in their study titled "To assess the 
severity of dengue fever in patients attending a tertiary care teaching hospital 
using WHO grading system" at Deccan college of Medical Sciences screened a 
total of 494 patients with suspected dengue fever were screened with ELISA 
IgM, IgG and MICROLISA test for NSI antigen diagnosed 131 cases (26%) as 
serologically positive for dengue fever.  Among the 131 patients 60% had DF, 
15% DHF grade I, 21% DHF grade II, 4.5% DSS III, and none in DSS IV.  IgM 
positive were 35 (27%), 63 (48%) were positive for both IgG and IgM and 65 
(50%) were NS1 Ag positive.   
 Platelet count of >1,50,000cells / cu.mm was found in 11% of cases and 
<50,000 in 38% and rest fell  in between:  Clinical manifestations included are 
fever (99%), followed by rash (22.13%).  Bleeding tendencies were noted in 
22% of cases, melena in 8%, hemetemesis 2%; 5% hematuria; 1% ecchymotic 
patches, 3% hematochezia. Signs of rising hematocrit in 73% patients, 
evidence of pleural effusion in chest radiograph in 25 patients, ascites in 15 of 
them, and hypoproteinemia in 10. 
 Anuradha M, Dendekar  RH, Banoo S 72 in their study titled "Laboratory 
Diagnosis and Incidence of Dengue Virus Infection: A Hospital Based study, 
Perambalur", done at a teaching hospital in Tamil Nadu screened a total of 151 
suspected cases of dengue fever over 1 year (March 2013 to February 2014) by 
NS1, IgM, IgG ELISA kit out of which 60 (39.74%) cases were seropositive.  
The peak incidence was found during the month of November followed by 
December.  
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 Kariyawasam S, Senanayake H 73 in their study titled "Dengue Infections 
During Pregnancy : Case series from a Tertiary care Hospital in Srilanka", 
diagnosed and studied a total of 15 pregnant women serology was done by IgM 
and IgG rapid strip test on serum samples obtained after 5-10 days after the 
onset of the clinical illness.  The age of the patients were between 22 to 41 
years.  3 of them were in their second trimester and the rest in their third 
trimester. IgM only was positive in 6 of them and IgM and IgG (Suggestion of 
secondary infection) were positive in 9 of the patients.  According to the WHO 
classification, 3 had DF, 3 had DHF grade I, 7 had DHF grade II, 2 developed 
DSS (1 had DHF II and the other had DHF IV). Fever was present in all the 
patients (100%), Myalgia (70%).  All the patient had thrombocytopenia (100%), 
Transaminase elevation (AST, ALT alone or both) were seen in all the patients 
(100%). Platelet transfusion was done in 8 patients (53.3%), 1 patient died of 
DSS.  2 patients had fetal mortality.  Rest of the mothers and children have 
done well with no evidence of morbidity or malformation seen in any of the 
children.  
 Saqib MA, Rafique I, Bashir S,  Salam SS 74 in their study quoted "A 
retrospective Analysis of Dengue Fever case management and frequency of 
Co-Morbidities associated with deaths" done in 2 major public sector tertiary 
care hospital during 2011 epidemic of DF in Lahore, Pakistan.  A total of 556 
who were dengue positive confirmed by IgM, IgG ELISA test were included out 
of the 390 (70%) were males and rest females.  The average age was 36 yrs 
and  the mean duration of stay in hospital was 6 days.439 (78%) were DF, 95 
(17%) DHF, 26 (4%) DSS.  The mortality among them was 7.2% (40 cases) out 
of these 17 were diagnosed with DSS. 26 (60%) of the deceased patients had 
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co-morbid diseases especially hypertension followed by diabetes.  DSS was 
found to be more common in those with essential hypertension.  The common 
clinical findings were fever in 100% of  DF, 93% in DHF and 100% in DSS in 
75% of DF, 25% in DHF and 92% in DSS; rash in 29% of DF, 25% of DHF, 58% 
in DSS.  Bleeding manifestation in 15% of DF, 59% of DHF and 72% of DSS 
patients.  Thrombocytopenia was observed (<10,0000) was observed in 515 
(93%) of patients but severe thrombocytopenia was seen in 29 (5%) of cases 
(<10,000 cells/cumm) platelet transfusion was done in 260 patients.  (192 DF, 
48 DHF and 20 DSS) out of which 19 patients had severe thrombocytopenia 
which 173 cases had platelet count in the range of 11,000  to 40,000 
cells/cumm.  About  68 (12%) of the patients were given platelet transfusion 
even with their count >40,000. 
 Saqib MA, Rafique I, Bashir S, Salam SS 76 in their study titled "Severity 
of Acute Hepatitis and its outcome in patients with Dengue fever in a Tertiary 
care Hospital Karachi, Pakistan".According to this study severe hepatitis 
complicating DF is a major contributor to life threatening haemorrhage, 
encephalopathy and disseminated intravasular coagulation (DIC).  The 
complications and mortality between patients with mild to moderate (ALT 
between 23-300 IU/L) versus severe hepatitis (ALT > 300 IU/L) were studied.  A 
total of 699 patients with dengue fever were included.  Out of them 605 (87%( 
and DF, 94 (13%) DHF or DSS.  Liver function test (LFT) revealed mean ALT of 
88.50 IU/L (range of 43.25 – 188 IU/L) ,AST of 174 IU/L (range of 87-371.5 
IU/L) and mean S.bilirubin of 0.8 mg/dl (range of 0.6-1.3mg/DL).   Overall 
mortality was 33.3% in moderate hepatitis group versus 66.7% in severe 
hepatitis group.  There was a considerable difference for complications like 
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bleeding (P value <0.001), acute renal failure (P value 0.002), acalculus 
cholecystitis (P.value 0.04) and encephalopathy (P Value 0.02) between mild / 
moderate to severe hepatitis group the average length of stay in hospital was 
3.63 days compared to 4.3 days in those who had  mild/moderate hepatitis and 
compared to patients with severe hepatitis . They concluded that severe 
hepatitis (SGPT-ALT of >300 IU/L) in DF is associated with prolonged in 
hospital  stay, bleeding, renal failure and mortality.  
Pruthvi D, Shashikala P, Shenoy V78 in their study titled "Valuation of 
Platelet count in Dengue Fever Along with Seasonal Variation of Dengue 
infection done at a teaching institution in Davangere, Karnataka, India, 
screened a total of 1549 patients experiencing febrile illness January 2009 to 
December 2009  for dengue infection. Out of them 264 (17.04%) cases were 
confirmed serologically positive for DF by IgM ELISA assay.  The peak 
incidence of DF were noted in the post monsoon time when there is relative 
drop in temperature as well as a rise in humidity.  Platelet counts were <25,000 
in 472 cases (30.47%) between 25,000 – 49,000 in 386 cases (24.91%), 
between 50,000 – 74,000 in 376 case (24.27), between 75,000 – 1,00,000 in 
169 cases (10.49%) and >1,00,000 in 146 cases (9.42%).  
 Khan MU, Rehman R, Gulfraz M, Latif Wet al80 in their study quoted 
"Incidence of Thrombocytopenia in Seropositive Dengue patients" at University 
of Health Sciences, Lahore, Pakistan. Samples were taken and screened from 
750 patients who presented with febrile illness consistent with dengue fever 
from September 2011 to January 2012 with IgM ELISA serology.  A total of 250 
patients were confirmed positive for DF. 1% of patients had mild to moderate 
hepatitis and 103 (15%) had severe hepatitis Among the 250 patients 2% had 
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severe thrombocytopenia, 65.2% had mild to moderate thrombocytopenia and 
32.8% had normal platelet counts (82 patients had normal platelet count), 5 
patients had severely low count i.e. < 25,000/cu.mm, 106 patients had 
moderately low counts i.e. between 25,000 – 1,00,000 cells/ cu.mm and 57 
patients had borderline reduction ie) between 1,00,000 to 1,50,000 cells/cu.mm.  
Bleeding manifestation was absent in normal and borderline thrombocytopenia 
groups (0%), present in moderately low (23%) and severely low (80%) groups. 
Bleeding manifestation and thrombocytopenia revealed no gender or age 
differences bleeding risk was significantly related to thrombocytopenia.  
 Khan M, Kuppusamy K, SumathiS et al83 in their study titled "Evaluation 
of Thrombocytopenia in Dengue infection along with seasonal variation in Rural 
Melmaruvathur" conducted at a teaching hospital in Melmaruvathur, Tamil 
Nadu, India between January 2011 to December 2012 screened a total of 1,464 
patients presented execute febrile illness consistent with dengue fever using 
dengue IgM ELISA serology test out of the 1464 patients, 107 (7.3%) tested 
positive for DF, 76 (71%) of the positive cases had thrombocytopenia 
(<1,00,000 cells / cu.mm) while the remaining 31 (19%) had platelet count of 
>1,00,000 cells/cu.mm.  Out of the 76 patients with thrombocytopenia 38 (50%) 
had mild thrombocytopenia (5,1000-1,00,000) 28 (36.8%) had moderate 
thrombocytopenia (20000-50000) and the rest 10 (13.2%) had severe 
thrombocytopenia (<20,000). On admission of the 107 seropositive cases, 58 
(54.2%) had DF, 38 (35.5%) had DHF and 11 (10.2%) had DSS.  
Thrombocytopenia was more pronounced in patients with DHF/DSS. 
Among the patients with thrombocytopenia  47.4% cases with mild 
thrombocytopenia, 42.3% with moderate thrombocytopenia and 100% with 
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severe thrombocytopenia presented with clinical features suggestive of 
DHF/DSS.  The incidence of seropositivity was predominantly seen during the 
post monsoon and monsoon period ie). premonsoon 15 cases (14%), monsoon 
31 cases (29%), and post monsoon 61 cases (57%). Follow up of cases 
revealed all cases of DF, and 31 case of DHF had complete recovery and 
remaining 18 cases (7 DHF & 11 DSS) were referred to a higher specialized 
centre for further management.  
Harrisons Text Book of Internal medicine states that an isolated platelet 
count of <50,000/µl is associated with minor risk of bleeding until the count 
drops below <10,000-20,000/µl. There is increased risk by bleeding when 
associated with coexisting coagulopathies, liver disease, platelet inhibiting drugs 
and infection.  The minimum threshold for platelet transfusion is <10,000/µl in 
otherwise stable patients.7 
Kulkarni N84, in her study of 232 patients of dengue at a medical college 
hospital in Karnataka during July 2011 to October 2011 , out of this 195 
(84.2%), 35 (15%), 02(0.8%) were DF, DHF, DSS respectively.  118(51%) 
cases received single unit of platelet transfusion between 20,000-1,000,00/µL 
and 64 (27.5%) patients who had platelet count of less than 20,000/µl received 
multiple platelet transfusion.  It was concluded that 51% of platelet transfusion 
are inappropriate and is more effective when it is given to patient with platelet 
count of <20,000µl.  
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The present study was conducted in the Department of Pathology, Sree 
Mookambika Institute of Medical Sciences, Kulasekharam, Kanyakumari 
District, Tamil Nadu.  In the present study the cases were taken from the 
Department of General Medicine, Sree Mookambika Institute of Medical 
Sciences, Kulasekharam.  Clinically suspected cases of dengue confirmed by 
serological studies of IgM ELISA with or without NS1 antigen positivity were 
taken and the various parameters were studied. They were followed from the 
day of admission to time of recovery or discharge. 
MATERIALS AND METHODS: 
a) Study design:     Descriptive Cross Sectional Study 
b) Study setting :SreeMookambika Institute of Medical Sciences  
c) Approximate total duration of the study: Two years(till sample size 
was reached)  
d) Number of groups  studied: One 
e) Detailed description of the groups: Patients in the age group 13 and 
above, attending the Medicine OPD of SMIMS, Kulasekharam, 
considering the inclusion and exclusion criteria. 
i) Inclusion criteria: 
1. All serologically positive dengue patients (Dengue IgM antibody,NS1 
antigen) 
2. Age 13 years and above. 
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ii) Exclusion criteria: 
1. Suspected dengue cases in which serology is found to be negative. 
2. Serologically positive cases of dengue who are also positive for other 
coexisting infections eg. Malaria, typhoid. 
3. Patients not giving consent. 
Statistical method of analysis:  
Mean, Standard deviation and Statistical parameters are calculated by 
utilizing statistical analysis package.  Suitable tests of analysis are analysed 
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Method(s)/Technique(s)/Instrument(s)/Reagent(s)/Kit(s) etc used to 
measure the quantitative parameters along with the manufacturing source 
details: 
NS1/IgM ELISA KIT: Manufacturer: Panbio, Inverness Medical 
Innovations, (Australia Pty Ltd,532 seventeen Miles 
Rocks Rd, Sinnamon Park, QLD 4073 Australia) 
Leishman’s stain: Manufacturer: Biolab diagnostics,Cochin-
25,Cochin.Phone No:9388619462 
Automated cell counter: Beckman Coulter Ac.T 5 Diff CP: Manufacturer: 
System Technologies, LLC, New Hope, MN, Phone 
number:763-537-3600. 
T- COAG KC1 DELTA: Trinity Biotech, IDA business park, Co Wicklow, 
Ireland.  Tel:+353 1 276 9800 
DENGUE NS1 CAPTURE ELISA: 
Principle 
 Serum dengue NSI antigen when present binds to anti-NS1 antibodies 
present on the polystyrene surface of microwells. Residual serum is removed by 
washing and  HRQ conjugated Anti NS1 MAb is supplemented.  After 
incubation, the microwells are washed and a colourless substrate system, 
tetramethylbenzidine / hydrogen peroxide (TMB chromogen) is  then added.  
The substrate is hydrolysed by the enzyme and the TMB becomes a blue 
colour.  After stopping the reaction with acid, the TMB turns yellow.  
Development  of colour is suggestive of the presence of dengue NS1 antigen in 
the test sample.  
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Materials  
1. Anti-NS1 Antibody coated microwells (12x8wells) 
2. HRP conjugated Anti-NS1 MAb – 1 bottle 15 ml 
3. Wash Buffer (20x) – One bottle of 20x concentrate of phosphate buffered 
saline (pH – 7.2-7.6) with Tween 20 and preservative (0.1% Proclin)  
4. Sample Diluent – one bottle, 22ml Brown 
5. TMB Chromogen (TMB) – one bottle 15ml 
6. Positive control – one purple – capped vial, 1.2ml of  recombinant 
antigen  
7. Calibrator – Two orange – capped vials, 1.5ml 
8. Negative control – one white capped vial, 1.2ml of  human serum.  
9. Stop solution – one Red – capped bottle, 15ml. 
Additional materials required but not provided.  
1. Accurate adjustable micropipetters which have disposable pipette tips (5 
– 100µl)  
2. Deionised water. 
3. Microplate washing system 
4. Microplate reader with 450nm filter  
5. Timer 
6. Graduated cylinder 
7. Flask 
8. Test tubes / microplate for dilutions.  
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Storage conditions  
 All reagents/materials are stored at 4oC.  
Specimen to be used 
 The test has to be done  on serum only.  The use of whole blood, plasma 
or  any other specimen matrix has not been recognized.  
ELISA PROCEDURE 
i) Pipette 100µL  diluted test sample and controls onto their 
respective microwells.  
ii) Cover the plate and incubate for 1hr at 37oC ± 1oC 
iii) Wash six times with diluted wash buffer. 
iv) Pipette 100µL HRP conjugated Anti NS1 MAb into each well.  
v) Cover plate and incubate for 1 hr at 37oC ± 1oC 
vi) Wash six times with diluted wash Buffer.  
vii) Pipette 100µL of TMB into each well. 
viii) Incubate for 10 minutes at room temperature (20 – 25oC), timing 
from the first addition.  A blue colour will develop. 
ix) Pipette 100µL of stop solution to all wells in the same sequence 
and timing as the TMB addition.  Mix well. The blue colour 
changes to yellow. 
x) In 30 minutes read the absorbance of each well at a wavelength of 
450nm with a reference filter of 600-650nm.  
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Quality Control 
 Each kit is supplied with one positive control and one Negative control 
and a calibrator.  
Interpretation of results  
Index Panbio Units Result 
< 0.9 < 9 Negative 
0.9 – 1.1 09 -11 Equivocal 
>1.1 >11 Positive 
 
DENGUE IgM CAPTURE ELISA: 
Principle: 
 The panbio ELISA kit contains a microtitre plate, which is precoated with 
dengue virus antigens.  At the time of the first incubation, anti dengue IgM 
antibodies in the diluted patients serum gets bound to dengue virus antigens.  
Following this incubation all the unbound material are removed by washing 
using an ELISA washer.  The presence of antidengue IgM antibody is detected 
by adding and incubating peroxidase enzyme labeled antihuman IgM.  This is 
followed by a washing step.  The enzyme activity can this be detected by 
adding chromogen/substrate solution (ie) Tetra Methyl Benzedine.  The 
absorbance is read at 540nm using ELISA microwell plate reader.   
The test was carried out the results were calculated according to the 
manufacturers instructions in the insert.  
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Content  
 Coated microplate wells  
 Positive control (IgM, human) 
 Negative control (IgM, human) 
 Calibrator 
 Enzyme conjugate  
 Sample buffer (has IgG/Rheumatoid factor (RF) – absorbent  
 Wash buffer 
 Chromogen/substrate (TMB/H2O2) 
 Stop solutions (0.5ml, sulphuric acid)  
Preparation of Reagents  
Preparation of wash buffer:  
 It has a strength of 10x, it was prepared by adding 1 part of reagent with 
9 part of deionized or distilled water.  
Preparation of patients sample  
 Patients serum sample has to be diluted using sample buffer in a ratio of 
1 = 101 before analysis.  For this 10µl of serum was added to 1.0ml of sample 
buffer and mixed well.  The sample buffer contains anti-human IgG antibody 
from goat.  The human IgG antibodies in the serum binds to the above 
antibodies and precipitate leaving only IgM antibodies.  This was allowed to 
incubate at room temperature for 10 minutes.  This step was done to remove 
IgG antibody and rheumatoid factors.  
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Procedure of ELISA 
1. The reagents are brought to room temperature (+18 to +25oC) before 
the commencement of the assay. 
2. Patients serum samples are processed as mentioned earlier in the 
preparation of patients samples.  
3. 100µl of calibrator, negative control , positive control and diluted 
patients samples are pipetted into individual microplate wells in 
accordance  to the pipetting protocol. 
4. Incubated at room temp (+18oc to 25oC) for 30 minutes 
5. Wash the reagent wells 3 times with 400µl working strength wash 
buffer. Leave the buffer in each well for 30 – 60 sec per washing 
cycle.  After washing to remove all liquid from microplate by tapping 
an absorbant paper with opening facing downwards.  
6. Pipette 100µl of enzyme conjugated (peroxidase labeled antihuman 
IgM) into each microplate well.  
7. Incubate at room temperature (+18o to 25oC) for 30 minutes.  
8. Wash as above  
9. Pipette 100µl of chromogen /substrate solution to each of the 
microtitre well.  
10. Incubate at room temperature (+18oC to 25oC) for 15 minutes (protect 
from direct sunlight)  
11. Pipette 100µl of stop solution into each of the microplate wells.  
12. Read the absorbance of wells with a bichromatic spectrophotometer 
at 450nm wavelength and reference wavelength between 620nm  and 
650nm within 30 minutes of addition of the stop solution. 
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Calculation of Results  
 The extinction value of calibrator defines the upper limit of the reference 
range of non infected persons (cut offs). Values above the indicated cut off are 
measured as positive, those below are considered negative.  
Semi Quantitative  
 Results  can be concluded semi quantitatively by calculating ratio of 
extinction value of the control or patient sample over the extinction value of 
calibrator.  
        
                                       
                        
 
Interpretation : 
 Ratio < 1.8  - negative 
 Ratio   1.8 to 22 – borderline 
 Ratio   2.2 – positive  
Additional materials required but not provided  
1. Accurate adjustable micropipettors with disposable pipette tips 
2. Microplate washing system 
3. Deinoised water 
4. Microplate reader with 450nm filter  
5. Graduated cylinder 
6. Timer 
7. Test tubes or microtitre plate for serum dilutions 
8.  Flask 
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ESTIMATION OF aPTT  PT- INR: 
Principle: 
Tissue thromboplastin in the existence of calcium activates the extrinsic 
pathway of the human blood coagulation system. When LIQUIPLASTIN reagent 
is added to normal anticoagulated plasma, the clotting mechanism is activated 
forming a solid gel clot within a specific period of time.  The time essential for 
clot formation would be protracted if there is a deficiency of factors/factor 
activity in the extrinsic pathway of coagulation system. 
Test procedure: 
1) Aspirate from the reagent vial for instantaneous testing requirements in a 
clean and dry test tube. 
2) To a 12x75mm tube add 0.1 ml of plasma 
3) To the tube place a steel ball and with force add 0.2 ml of LIQUIPLASTIN 
reagent and simultaneously press start and the tube is automatically 
rotated. 
4) Stop the machine as soon as the first fibrin strand is visible and the 
gel/clot formation begins 
5) Time is recorded in seconds. This gives the prothrombin time, aPTT 
values are also noted. 
6) INR is calculated from the PT ratio using a thromboplastin with a known 
ISI. 
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ESTIMATION OF HAEMATOLOGICAL PARAMETERS: 
Estimation of haematological parameters like Hb%,PCV,WBC count, 
platelet count, differential count were done by automated cell counter (Beckman 
Coulter Ac.T 5 Diff). 
PERIPHERAL SMEAR STAINING AND EXAMINATION: 
Blood smears are prepared from EDTA blood and are stained by 
Leishman stain 
The components of Leishman stain are: 
1. Methylene blue  
2. Eosin 
3. Absolute methyl alcohol 
Procedure: 
 Air dry the smear and cover the smear with Leishman stain for two 
minutes 
 After two minutes add twice the volume of buffered water and leave 
for 5-7 minutes. 
 A scum of metallic sheen forms on the surface. 
 Wash the stain away in tap water 
 Wipe the back of the slide clean and set it upright on a draining rack 
to dry.  
 Mount the slide with DPX with a clean and dry 25x25mm cover slip 
 The slide is then examined.     
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Source of data: 
The present study is carried out in 50 cases of serologically positive 
dengue patients in the Department of Pathology, Sree Mookambika Institute of 
Medical Sciences, Kulasekharam, TamilNadu. 
Method of collection of Data: 
 The study is done in collaboration with the Department of Medicine.  
 Clinically suspected cases of dengue will be screened and their consent 
for the study obtained. 
 Patients clinical data were collected from the medical records. 
 Data was then be collected in a predesigned questionnaire. 
 2-5ml of venous blood is collected in vaccum tubes or disinfected vials 
with screw caps and gasket. 
 Adhesive tape marked with pencil, permanent ink or a type 
written/printed self adhesive label to recognize the container.  The name 
of the patient, identification number and date of collection will be 
indicated on the label 
  Serological confirmation by dengue specific NS1 antigen assay and/or 
IgM by ELISA was done.  In this method the plate is sensitized with the 
antigen.  It is then washed and the test antibody is added. Another wash 
is given and a chromogen is added.  The results are quantitated by 
colorimetric scanning of the plate.  
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 Clinical  parameters of each serologically dengue positive patient was 
recorded. 
 Other haematological parameters like Haemoglobin, Packed cell volume,  
Total WBC count, Differential WBC count was done by automated cell 
counter and recorded. 
 Platelet count was  done by automated cell counter  . If flagging  occurs 
for the values manual count will be done.  
 Peripheral smears were made and stained with Leishman’s stain and the 
report of the smear was recorded. 
 Biochemical parameters like AST, ALT, aPTT, PT,S. Bilirubin,, BUN,S.  
Creatinine, and Blood glucose  values was recorded. 
 An observation on the number of dengue positive patients who require 
and receive platelet transfusion as per the treatment norms for dengue 
patients in the Medicine department of SMIMS was made and the details 
of the transfusion noted. 
 The patients who were observed to receive platelet transfusion were 
followed up with repeated platelet counts (for which 2ml of venous blood 
will be drawn) and  results of the platelet count and outcome noted.  
The data obtained was tabulated in the master chart with the various 
parameters to be observed and studied. 
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Age distribution: 
Out of fifty cases of serologically positive dengue cases studied 8(16%) 
cases were in the age group of 14-20 years,13(26%) were in the age group  
21-30 years,13(26%) were in the age group 31-40 years,7(14%) were in the 
age group of 41-50 years,3(6%) were in the age group of 51-60 years,5(10%) 
were in the age group of 61-70 years and one (2%) case was above 70 years of 
age.(Table 1,Figure 1) 
In my study the commonest age group was from the age of 14-40 years. 
Gender distribution: 
Out of the 50 cases studied 29(58%) were males and 21(42%) were 
females.(Table 2 ,Figure 2) 
In my study there was a slight male preponderance. 
Fever duration distribution: 
Out of the fifty cases studied patients who had fever for 5 days duration 
were 13(26%),fever for 6 days were 17(34%),fever for 7 days were 
12(24%),fever for 8 days were 3(6%),fever for 9 days were 1(2%) and fever for 
10 days duration was 4(8%).(Table 3,Figure 3) 
5-6 days was the most common fever duration in my study. 
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Musculoskeletal complaints distribution: 
Out of the fifty cases studied 50(100%) of the patients had headache, 
43(86%) had myalgia ,7(14%) had retroorbital pain, and 5(10%) had 
arthralgia.(Table 4) 
Respiratory complaints distribution: 
Out of the fifty cases studied 6(12%) of the patients had upper 
respiratory tract infection, 8(16%) had lower respiratory tract infection.(Table 5) 
Gastrointestinal complaints distribution: 
Out of the fifty patients,14(28%) had abdominal pain,20(40%) had 
vomiting,26(52%) had hepatomegaly and 24(48%) had splenomegaly.(Table 6) 
Haemorrhagic manifestation distribution: 
Out of the fifty cases studied only one(2%) of the patients had major 
bleeding manifestation.8(16%) of patients had minor bleeding manifestations 
and 41(82%) had no bleeding manifestation.(Table 7,Figure 4) 
Signs of capillary leak distribution: 
Out of the fifty cases studied,8(16%) of cases had pleural effusion,13(26%) had 
ascitis and 8(16%) had rising haematocrit.(Table 8) 
Serological positivity distribution: 
Out of the fifty cases studied 29(58%) showed positivity for IgM and 
21(42%) showed positivity for NS1 and IgM.(Table 9,Graph 5) 
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Mean values of haematological examination:  
In the fifty cases studied the mean values of haemoglobin was 12.78 with 
a S.D value of 1.71,PCV was 36.25 with a S.D of 6.28,WBC count was 4998.80 
with a S.D value of 2.52.The platelet count mean was 25220.74 with a S.D 
value of 4.62.The mean value for aPTT was 37.18 with a S.D value of 1.07.The 
PT INR mean value was 1.14 with a S.D value of 0.44.(Table 10,Graph 6) 
Mean values of differential count: 
In the fifty cases studied the mean values for polymorphs were 52.32 
with S.D value of 1.30,mean value for lymphocytes was 30.52 and S.D of 
1.16,mean value of eosinophils was 2.08 and S.D of 2.58.The mean value for 
monocytes is 14.07 and S.D is 10.28 and mean value for basophils was 1.69 
with S.D value of 1.83(Table 11,Graph 7) 
Peripheral smear examination distribution: 
In the fifty patients studied 4(8%) had anemia,3(6%) had 
leukopenia,16(32%) had thrombocytopenia,18(36%)  had leukopenia with 
thrombocytopenia,8(16%) had anemia with thrombocytopenia and 6(12%) of 
the patients had anemia with leukopenia and thrombocytopenia.(Table 12) 
Distribution of patients according to grade of thrombocytopenia: 
In the 50 patients studied 48 patients show thrombocytopenia .12(25%) 
showed Grade 1 thrombocytopenia,5(10.42%) Grade 2,22(45.83%) Grade 3 
and 9(18.75%) Grade 4.(Table 13,Graph 8) 
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 WBC count distribution:  
In the fifty cases studied Leukopenia was observed in 22(73%) of the 
patients,Leukopenia with reversal of neutrophil lymphocyte ratio was observed 
in 6(20%) of the patients,2(7%) had only reversal of neutrophil lymphocyte 
ratio.(Table 14,Graph 9) 
Mean values of biochemical examination: 
The various biochemical parameters observed in this study,blood 
glucose with a mean of 141.60 and S.D of 7.71,AST mean value of 106.08 with 
a S.D of 8.96,ALT mean value of  118.54 and S.D of 9.63,total bilirubin mean 
value of 3.47 and S.D of 1.46,urea mean value 32.70 with S.D of 1.95 and 
mean value for creatinine 1.15 with S.D 1.12.(Table 15) 
Distribution of patients administered platelet transfusion according to 
indication : 
In this study among fifty patients the patients where platelet transfusion 
was indicated were 43(86%).Thrombocytopenia was observed in 
48(96%).(Table 16) 
 Distribution of patients according to initiation of platelet  transfusion: 
In this study 2(4%) patients had platelet transfusion on the day of 
admission,26(52%) on the first day after admission,8(26%) on the second day 
after admission and 7(14%) on the third day after admission.(Table 17) 
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Distribution of patients according to units of platelets transfused: 
In this study 27(54%) of the patients were infused 1-2 units of 
platelets,5(10%) of patients were given 3-4 units of platelets,8(16%) of patients 
were given 5-6 units,2(4%) were given 7-8 units of platelets and 1(2%) was 
given 9-10 units.(Table 18,Graph 10) 
Distribution of patients according to the number of days of return to 
normal platelet count: 
In this study of 50 patients,43 were transfused platelets 3(6.98%) took 2 
days for platelet count to return to normal levels,23(53.49%) took 3 
days,9(20.93%) took 4 days,3(6.98%) took 5 days and 5(11.63%) took 6 
days.(Table 19,Graph 11) 
Distribution of patients according to diagnosis:   
In this study of fifty patients 29(58%) had dengue fever and 21(42%) 
were diagnosed as DHF.(Table 20,Graph 12) 
Distribution of patients according to recovery from dengue fever: 
In the fifty patients studied 4(8%) of patients took less than 7 days to 
recover from dengue fever,45(90%) took 7-13 days to recover and 1(2%) took 
14 days.(Table 21,Graph 13) 
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STATISTICAL ANALYSIS  
 
 
Table-1: Distribution of patients according to age 
 
Age (years) Number Percentage (%) 
14-20  08 16.00 
21-30 13 26.00 
31-40 13 26.00 
41-50 07 14.00 
51-60 03 06.00 
61-70 05 10.00 
Above 70 01 02.00 
 
 
Age group ranging from 21-40 showed the maximum distribution 
 
 
 
 
 
 
Table-2: Distribution of patients according to gender 
  
Gender Number Percentage (%) 
Male 29 58.00 
Female 21 42.00 
 
 
Males were more affected than females 
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Table-3: Distribution of patients according to duration of fever 
 
Duration of fever Number Percentage (%) 
5 days 13 26.00 
6 days 17 34.00 
7 days 12 24.00 
8 days 03 06.00 
9 days  01 02.00 
10 days  04 08.00 
 
 
Days 5-6 showed the maximum percentage. 
 
 
 
 
 
 
Table-4: Distribution of patients according to musculoskeletal complaints 
 
Musculoskeletal 
complaints 
Number Percentage (%)  
Headache 50 100 
Retro orbital pain 07 14.00 
Myalgia 43 86.00 
Arthralgia  05 10.00 
 
Headache was seen in 100% of patients followed by myalgia. 
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Table-5: Distribution of patients according to respiratory complaints 
 
Respiratory complaints Number Percentage (%) 
Upper respiratory tract infection  06 12.00 
Lower respiratory tract infection 08 16.00 
Dyspnoea 00 00.00 
 
 
More number of people (16%) were affected with lower respiratory 
tract infection. 
 
 
 
 
 
 
Table-6: Distribution of patients according to gastrointestinal complaints 
 
Gastrointestinal complaints Number   Percentage (%) 
Abdominal pain 14 28.00 
Vomiting 20 40.00 
Diarrhoea 07 14.00 
Hepatomegaly 26 52.00 
Splenomegaly  24 48.00 
 
 
Hepatomegaly was seen in 52% of patients 
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Table-7: Distribution of patients according to hemorrhagic manifestation 
 
Hemorrhagic manifestation Number Percentage (%) 
Major 1 02.00 
Minor 8 16.00 
Absent  41 82.00 
 
 
16% showed minor bleeding manifestations like petichiae and 
bleeding gums 
 
 
 
 
 
 
Table-8: Distribution of patients according to signs of capillary leak 
 
Signs of capillary leak Number Percentage (%) 
Pleural effusion 8 16.00 
Ascites 13 26.00 
Rise of hematocrit  8 16.00 
 
 
Rise in haematocrit is seen in 16% of the patients,Ascites in 26%. 
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Table-9: Distribution of patients according to serological examination 
 
Serology examination Number Percentage (%) 
NS1(Nonstructural protein -1) 0 00.00 
IgM (Immunoglobulin M) 29 58.00 
NS1+IgM 21 42.00 
 
 
IgM positivity was seen in 58% of cases,NS1 and IgM positivity seen 
in 42% of cases. 
 
 
 
Table-10: Mean values of hematological examination 
 
Hematological examination (MEAN±SD) 
Hb%(gm/dl) 12.78±1.71 
PCV(L/L) 36.25±6.28 
WBC(cells/cu.mm) 4998.80±2.52 
Platelet count(cells/cu.mm) 25220.74±4.62 
APTT(seconds) 37.18±1.07 
PT INR(ratio) 1.14±0.44 
 
 
Mean platelet count was 25,220.74 
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Table-11: Mean values of differential count 
 
Differential count (%) (MEAN±SD) 
Polymorphs 52.32±1.30 
Lymphocytes 30.52±1.16 
Eosinophils 02.08±2.58 
Monocytes 14.07±10.28 
Basophils  01.69±1.83 
 
 
Mean DC values were Polymorphs(52.32%),Lymphocytes(30.52%). 
 
 
 
 
 
Table-12: Distribution of patients according to peripheral smear 
examination 
 
Peripheral smear examination Number Percentage (%) 
Anemia 04 08.00 
Leukopenia 03 06.00 
Thrombocytopenia  16 32.00 
Leukopenia with Thrombocytopenia 18 36.00 
Anemia with Thrombocytopenia 08 16.00 
Anemia+ Leukopenia + Thrombocytopenia 06 12.00 
 
 
Thrombocytopenia was seen in 96% of cases 
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Table-13: Distribution of patients according to grade of thrombocytopenia  
 
Grade of thrombocytopenia Number Percentage (%) 
Grade-1 (75,000 to 1,50,000) cells/cu.mm 12 25.00 
Grade-2 (50,000 to less than 75,000) 
cells/cu.mm 
5 10.42 
Grade-3 (25,000 to less than 50,000) 
cells/cu.mm 
22 45.83 
Grade-4 (less than 25,000) cells/cu.mm 9 18.75 
 
 
Grade 3 showed 45.83% of cases 
 
 
 
 
 
Table 14: Distribution of patients according to WBC count and distribution 
 
WBC count and distribution Number Percentage (%) 
Leukopenia (<4000 cells/cu.mm) 22 73.00 
Leukopenia with reversal of neutrophil 
lymphocyte ratio 
6 20.00 
Reversal of neutrophil lymphocyte ratio 2 07.00 
 
 
Leukopenia was seen in93% of cases and 27% showed reversal of 
neutrophil lymphocyte ratio. 
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Table-15: Mean values of biochemical examination 
 
Biochemical examination (MEAN±SD) 
Blood glucose(mg/dl) 141.60±7.71 
AST(IU/L) 106.08±8.96 
ALT(IU/L) 118.54±9.63 
Total Bilirubin(mg/dl)  03.47±1.46 
Urea(mg/dl) 32.70±1.95 
Creatinine (mg/dl) 01.15±1.12 
 
 
Mean AST levels were 106.08 IU/L and ALT levels were 118.54IU/L 
 
 
 
 
 
Table-16: Distribution of patients administered platelet transfusion 
according to indication 
 
According to indication of platelet 
transfusion 
Number Percentage (%) 
Indicated 43 86.00 
Thrombocytopenia  48 96.00 
 
 
86% of the patients were transfused platelets. 
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Table-17: Distribution of patients according to day of initiation of platelet 
transfusion 
 
Day of initiation of platelet transfusion Number Percentage (%) 
0 day 02 04.00 
1st day 26 52.00 
2nd day 08 16.00 
3rd day 07 14.00 
 
 
Most of the patients were transfused during first or second day 
 
 
 
Table-18: Distribution of patients according to units of platelet transfused 
 
Units of platelet transfusion Number Percentage (%) 
1-2 units 27 54.00 
3-4 units 05 10.00 
5-6 units 08 16.00 
7-8 units 02 04.00 
9-10 units 01 02.00 
 
 
54% of the cases received 1-2 units of platelets 
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Table-19: Distribution of patients according to the number of days to 
return to normal platelet count 
 
Number of days Number Percentage (%) 
2 days 03 6.98 
3 days 23 53.49 
4 days 09 20.93 
5 days 03 6.98 
6 days  05 11.63 
 
 
Most patients had return of platelet count to normal levels by the 3rd 
or 4th day 
 
 
 
 
 
Table-20: Distribution of patients according to diagnosis 
 
Diagnosis Number Percentage (%) 
Dengue fever 29 58 
Dengue hemorrhagic fever 21 42 
 
 
58% of the patients were diagnosed as dengue fever and 42% of the 
cases as dengue haemorrhagic fever.  
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Table-21: Distribution of patients according to recovery from dengue fever 
 
Number of days Number Percentage (%) 
Less than 7 days 04 08.00 
7-13 days  45 90.00 
 14 days  01 02.00 
 
 
90% of the cases recovered within 7-13 days 
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Graph-1: Percentage of patient’s distributed according to age 
 
 
 
 
 
 
 
Graph-2: Distribution of percentage of patients according to gender 
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Graph-3: Distribution of percentage of patients according to duration of 
fever 
 
 
 
 
 
 
Graph-4: Distribution of percentage of patients according to hemorrhagic 
manifestation 
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Graph-5: Distribution of percentage of patients according to serological 
examination 
 
 
 
 
 
Graph-6: Mean value of WBC and platelet count 
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Graph-7: Mean values of differential count 
 
 
 
 
 
 
Graph-8: Distribution of percentage of patients according to grade of   
thrombocytopenia 
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Graph-9: Distribution of patients according to WBC count and distribution 
 
 
 
 
 
 
 
Graph-10: Distribution of percentage of patients according to units of 
platelet transfusion 
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Graph-11: Distribution of percentage of patients according to the number 
of days to return to normal platelet count 
 
 
 
 
Graph-12: Distribution of percentage of patients according to diagnosis 
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Graph-13: Distribution of percentage of patients according to recovery 
from dengue feve  
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DENGUE PERIPHERAL SMEAR 
 
  
Fig 1:Peripheral blood smear showing severe thrombocytopenia and   
leukopenia(100 X)  
 
 
 
 
Fig 2:Peripheral blood smear showing severe thrombocytopenia with tear 
drop cells,crenated RBC’s (100 x) 
 
DENGUE PERIPHERAL SMEAR 
 
 
Fig 3:Another case of thrombocytopenia with severe  
thrombocytopenia and leukopenia(100x) 
 
 
 
Fig 4: Peripheral blood picture showing closely packed RBC’s due to 
haemoconcentration (100x) 
 
 
DENGUE PERIPHERAL SMEAR 
 
Fig 5:Peripheral blood smear showing microcytic hypochromic RBC’s 
with moderate to severe thrombocytopenia(100x) 
 
 
Fig 6:Peripheral blood picture showing lymphocytosis and microcytic 
hypochromic RBC’s(100x) 
 
DENGUE PERIPHERAL SMEAR 
 
Fig 7:Microcytic hypochromic blood picture with mild 
thrombocytopenia(100x) 
 
 
 
 
                 Fig 8: Marked thrombocytopenia with leucopenia(100x) 
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Dengue fever remains the most important of the arboviral infections with 
significant socioeconomic and healthcare implications.  The clinical spectrum 
ranges from non-specific viral syndrome to classical dengue fever to life 
threatening  denguehaemorrhagic fever and dengue shock syndrome.  Early 
diagnosis and aggressive management especially for DHF and DSS remains 
the cornerstone strategy for successful outcomes. 
A total of 50 patients admitted to our hospital with symptoms of dengue 
fever and positiveNS1/ IgM ELISA were studied 
Age: 
The average age of patients in our study group was 36.84   years.  In the 
study by Nadeem MA et al.74the mean age was 36 years, where as the mean 
age was 34.7 years according to the study by Tiwari KN et al.57 
Gender: 
Out of the 50 cases included in our study 29(58%) were males and 
21(42%) were females.in comparison the study done by Nadeem MA et.al 74 the 
gender ratio was 390(70%) in males and 166(30%) in females of the 556 
cases.The sex distribution study by Raju BJ et.al58 were as follows,out of the 
200 patients included 121 (60.5%) were males 79(39.5%) were females.Our 
studies had a male preponderance in comparison to the other studies. 
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CLINICAL FEATURES: 
Fever: 
All patients in our study presented with fever on admission.Similarly 
studies done by Turbadkar D et .al ,68Mandal SK et. al ,70Karyawasam S et al 
73,Nadeem MA et .al,74Tiwari KN et .al57 and Raju BJ et .al 58 had all their 
patients(100%) with fever  followed by Fatima S et .al 71(99%),Lt Col. Banerjee 
M et.al 63 (85 %) and Khan AH et.al 69 (80%).Our study correlated well with 
most of the studies. 
Headache: 
Headache was universally present among all our patients (100%).In 
other studies the incidence of headache was as follows ,Raju BJ et. al 58 (98%), 
Lt .Col. Banerjee M et .al 63(63%), Mandal KS et.al 70 (62.16%), Khan AH et 
al69(50%),Turbadkar D et .al68(13.9%).Our study differed from most of the other 
studies as headache was not a prominent symptom in those studies. 
Retroorbital pain: 
          This symptom is considered a hallmark of Dengue fever.The number of 
patients in our study manifesting this were 7(14%) out of the 50 cases. Raju BJ 
et.al58 in their study of 200 dengue cases reported a 26.5% of incidence of 
retroorbital pain. 
Myalgia: 
Our study revealed that 43(86%) out of 50 patients had myalgia.Studies 
done by Raju BJ et.al 58 had 85.5% of patients having myalgia,Lt.Col.Banerjee 
M et .al 63(81%), KariyawasamS etal73(70%), Turbadkar D et al68(25%),.Tiwari 
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KN et al57(24%) and Khan AH et al69(10%) of the patients presented with 
myalgia. 
Arthralgia: 
5(10%) of the patients had arthralgia. Raju BJ et.al 58 reported a 
incidence of 16% among their study group. 
RESPIRATORY COMPLAINTS: 
URTI/LRTI: 
We encountered 6(12%) of our patients with URTI; and 8(16%) had 
lower respiratory tract infection. Khan AH et al 69 reported 35% manifesting as 
URTI in their study. 
GASTROINTESTINAL COMPLAINTS: 
Abdominal pain: 
            We had 14(24%) of patients with abdominal pain. Raju BJ et.al58 has 
had an incidence of 55% and Tiwari KN et .al57 with 34% of the patients 
presenting with abdominal pain 
Nausea and vomiting: 
20(40%) of our patients experienced the above mentioned symptoms. 
Raju BJ et al58 reported a incidence of (84.5%), Khan AH et.al69(60%), Tiwari 
KN et .al57(36%). 
Diarrhoea: 
Loose stools were seen in 7(14%) of the patients.None of the other 
studies reported diarrhea in their study group. 
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Hepatomegaly: 
Hepatomegaly was observed in 26(52%) of our patients. Raju BJ et .al58 
(30%) and Lt.Col.Banerjee.M et.al 63reported an incidence of 15% among their 
patients.  
Splenomegaly: 
Enlarged spleen was palpable in 24(48%) our patients.Lt.Col. Banerjee 
M et.al 63 reported splenomegaly in 7% of the patients. 
SIGNS OF CAPILLARY LEAK: 
Evidence of capillary leak is the hallmark of DHF and DSS .The three 
common signs are a rising hematocrit,ascites and pleural effusion. 
Pleural effusion: 
Pleural effusion was assessed by either chest radiograph or by 
ultrasound examination.8(16%) of our patients had pleural effusion. Fatima S 
et.al71 reported a incidence of 19%(25 out of 131 cases) 
Ascites: 
Ascites was assessed by ultrasonographic examination.A total of 
13(26%) patients had ascites in our study group. Raju BJ et.al 58 reported a 
incidence of 21.5% out of 121 dengue positive patients  Fatima S et.al71 
reported an incidence of 11.5% (15 out of 131 cases) in their study. 
Rising haematocrit: 
Significant or rising haematocrit  was seen in 8(16%) of our patients. 
Fatima S et.al71 reported an incidence of 73% in their study. Nadeem MA et.al74 
in their analysis of dengue patients at two major public sector tertiary care 
 
 DISCUSSION 
 
95 | P a g e  
 
hospitals in Lahore,Pakistan, reported a rising haematocrit in 21% of patients 
out of 390 patients. 
SEROLOGY: 
              We confirmed a diagnosis of dengue fever with NS1 ELISA and IgM 
ELISA tests, but included patients who were IgM positive.Out of the 50 patients 
29(58%) were IgM only positive and the rest 21(42%) were both NS1 and IgM 
positive. Bandyopadhyay B et.al55 in their study at Calcutta School of Tropical 
Medicine,screened patients suggestive of DF with NS1 and IgM ELISA test and 
included 64 patients out of which 38 were NS1 positive.Out of the 38 cases,24 
were found to be IgM positive and the rest 14 cases were IgM ELISA 
negative.This was attributed to the possible secondary dengue infection where 
the IgM titres sometimes become undetectable. Fatima S et.al 71 screened 
patients with the symptoms of dengue fever with IgM ,IgG ELISA and NS1 
ELISA tests and included 131 cases who wre serologically positive for DF.Out 
of the 131 patients 35(27%) were positive for IgM only,63(48%) positive for both 
IgM and 65(50%) were NS1 positive.  Turbadkar D et.al65,screened a total of 
3,677 patients with symptoms consistent with DF with IgM and IgG ELISA tests 
and found a total of 503 serologically positive cases .Out of these 288(57.25%) 
were positive for IgM ELISA alone ,followed by 108 cases (21.4%) for IgG 
ELISA and 107 (21.4%) for both IgM and IgG ELISA.The authors have excluded 
patients with isolated IgG positivity as it may be due to a remote dengue 
infection. 
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HAEMATOLOGICAL PARAMETERS: 
Anemia: 
Our study revealed an incidence of 8%(4 patients) whereas the study 
conducted by Lt.Col.Banerjee M.et.al 63 revealed an incidence of 11%  in 50 
patients studied. 
Leukopenia: 
Leukopenia was seen in 22 (44%) of our patients,whereas in the study 
by Lin SF et.al 67,the incidence of leucopenia was 76% in patients with dengue 
fever.According to a study by Lt.Col.Banerjee M et.al63,none of the 50 cases of 
DF manifested leucopenia. 
Thrombocytopenia: 
Thrombocytopenia was observed in 48 (96%) in our study,Based on the 
grading 12(25%) of cases showed grade 1 thrombocytopenia,5(10.42%) 
showed grade 2,22(45.83%) Grade 3 and 22(45.83%) Grade 4.Turbadkar 
D.et.al 68 in their study of 212 patients reported an incidence of 76.74% of 
thrombocytopenia.Sarwat Fatima et.al 70 reported thrombocytopenia to the tune 
of 89% in their study involving a total of 131 seropositive patients. Kariyawasam 
S et.al 73 reported a100% incidence of thrombocytopenia in their study involving 
15 pregnant patients who were seropositive for DF. Nadeem MA et.al 74 in their 
study reported an incidence of 93% of thrombocytopenia in their study involving 
556 seropositive patients during the 2011 dengue fever epidemic in 
Lahore,Pakistan. Khan MU et.al 80 in their study quoted a 67.2% 
thrombocytopenia among 210 seropositive dengue positive patients. Khan DM 
et.al 83 reported an incidence of 71% thrombocytopenia. 
 
 DISCUSSION 
 
97 | P a g e  
 
BIOCHEMICAL PARAMETERS:  
Liver function tests: 
Hyperbilirubinemia (S.Bilirubin ) was seen in 12(24%) of the patients in 
our study.None of the studies quoted have described jaundice in these patients. 
SGOT(AST) AND SGPT(ALT): 
Transaminitis was encountered in many of our patients.SGOT levels 
were elevated in 39(78%) and elevated SGPT levels were seen in 38(76%) of 
our patients. Mandal SK et .al70 in their study reported transaminitis of 83.83%. 
Kariyawasam S et.al73 reported a 100% incidence of elevated liver 
enzymes(SGOT,SGPT) in their study involving 15 seropositive pregnant 
women.In our study the mean SGOT(AST) levels were 141.60 IU/L.SGPT(ALT) 
levels were 118.54 IU/L. Prakash O et.al 76 in their exclusive study of hepatitis in 
dengue fever in a tertiary care hospital  in Karachi,Pakistan,involving 699 
seropositive cases reported a mean SGOT(AST) of 174 IU/L and SGPT(ALT) of 
88.50 IU/L. 
COAGULATION PROFILE: 
Prothrombin Time(PT-INR) and activated partial Thromboplastin 
time(aPTT) : 
The normal prothrombin time INR value is 0.8 to 1.2 .7(14%) of our 
patients had prolonged prothrombin time. 
Activated partial thromboplastin time(aPTT) was prolonged in 10(20%) of 
our patients.None of the studies reported significant abnormalities in 
coagulation profile. 
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RENAL FUNCTION TESTS: 
Serum urea and creatinine: 
We have encountered mild renal failure in few of our patients who all had 
complete recovery of renal function during discharge or followup.Blood urea 
was elevated in 10(20%) and serum creatinine was elevated in 9(18%) of the 
patients.There is no clear data regarding this in those studies quoted. 
PLATELET TRANSFUSION: 
Indication: 
A total of 43 patients (86%) received platelet transfusion in our study 
group.The sole indication being moderate to severe thrombocytopenia. 
Tiwari KN et.al 57 in their retrospective study thrombocytopenia was the 
common indication for platelet transfusion in 4 tertiary care hospitals in Delhi.A 
total of 230 seropositive cases were included and out of which 130 
cases(56.5%) received platelet transfusion.The common indication was 
thrombocytopenia rather than bleeding manifestation. Kulkarni.N.84 in her study 
118(51%) out of 232 patients received single unit platelet transfusion with 
platelet counts between 20,000 and 1.00.000cells/cu.mm and 64(27.5%) with 
platelet of <20,000 cells/cu.mm received multiple platelet transfusions.It was 
concluded that 51% of platelet transfusions were inappropriate and more 
effective when it is given with a platelet count of <20,000cells/cu.mm. 
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Units of platelets transfused: 
In our study 54%(27) received 1-2 units,10%(5) received 3-4 
units,16%(8) of cases were given 5-6 units,4%(2) were given 7-8 units and 
2%(1) received >9 units of platelet transfusion.The mean units of platelets 
transfused is 2.42 units .The average number of days of hospital stay for those 
who received platelet transfusion 5 days and who had not receive platelet 
transfusion  was 3.7 days. Tiwari KN et .al 57 in his study of 230 seropositive 
dengue patients 130 received platelet transfusion,the minimal units of platelets 
transfused was one and maximum of 16 units was transfused.The average 
number of days in the hospital for those who received platelet transfusion was 
4.9 days as compared to a longer duration of hospital stay(5.3days) for those 
who did not receive platelet transfusion. Kulkarni.N.84 in her study 118(51%) out 
of 232 patients received single unit platelet transfusion with platelet counts 
between 20,000 and 1.00.000cells/cu.mm and 64(27.5%) with platelet of 
<20,000cells/cu.mm received multiple platelet transfusions.It was concluded 
that 51% of platelet transfusions were inappropriate and more effective when it 
is given with a platelet count of 20,000. 
PROFILE: 
            The number of patients who had dengue fever were 29(58%) out the 
total 50 patients and DHF was 21(42%).None of the patients had DSS in our 
study group. Fatima S et.al71 in their study of 131 seropositive dengue case had 
DF(60%) ,DHF(35.5%)  and DSS(4.5%). Arif M et .al 74 in the study of 556 
seropositive dengue cases 439(78%) had DF,95(17%) had DHF and 26(4%) 
has DSS. Khan DM et.al 83 in their study of 107 seropositive cases in a teaching 
 
 DISCUSSION 
 
100 | P a g e  
 
hospital in rural Melmaruvathur in Tamilnadu,out of these 58(54.2%) had 
DF,38(35.5%) had DHF and 11(10.2%) had DSS. 
Hati AK et.al 56 in their study in West Bengal had 90% of patients having 
DF and 10% had DHF. Tiwari KN et al57 in their study based in Delhi,included 
230 seropositive cases.Out of these 163(70.8%) had DF and 29.2% had DHF.  
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Dengue has evolved into a truly global arboviral illness with ever 
increasing multiple epidemics and a rising incidence of severity in the form of 
Dengue Haemorrhagic Fever throughout the tropics and subtropics with an 
impending risk of invading the temperate regions in this era of climate change 
and global warming. 
Our study focused on the haematological profile of dengue fever in 
correlation with the  clinical course. It was concluded in this study that fever with 
headache in the presence of thrombocytopenia ,leukopenia and reversal of 
neutrophil lymphocyte ratio should raise a strong suspicion of Dengue fever for 
which screening  and  confirmation  must be done. 
Signs of capillary leak like rising haematocrit, ascites and pleural effusion 
should alert the treating physicians  for prompt and aggressive management for 
the high risk of Dengue Haemorrhagic Fever. 
Thrombocytopenia and  a rising haematocrit (PCV) by 20% from baseline 
were found to be important prognostic indicators during hospital stay and 
followup. 
Platelet transfusion, another focus of this study, was initiated in patients 
with moderate to severe thrombocytopenia.  The patients had a smooth and 
rapid recovery with no adverse outcomes related to the transfusion. 
All patients with abnormalities in the clinical, haematological and 
biochemical parameters in our study group made a complete recovery either 
during the hospital stay or within the follow up period. 
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In conclusion early suspicion, screening, diagnosis and prompt 
management of Dengue fever will effectively lower any morbidity or mortality 
related to this dreaded illness. 
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 A total of 50 patients who were admitted with fever and IgM ELISA with or 
without NS1 antigen positivity were studied. 
 Out of the fifty patients 29(58%) were diagnosed to have dengue 
fever(DF),and the rest 21(42%) had Dengue Haemorrhagic Fever(DHF) 
 The age distribution was between14-70 years with more than 50% falling 
between 21-40 years age group. 
 The male to female ratio is 1.3:1 in this study. 
 The common clinical manifestations were fever(100%) and 
headache(100%),followed by myalgia(86%),hepatomegaly(52%) and 
splenomegaly(48%). 
 The common signs of capillary leak were ascites (26%),rising haematocrit 
and pleural effusion each (16%) 
 Bleeding manifestations commonly encountered were minor manifestations 
like petichiae(16%),only (2%) had major bleeding manifestation like GI 
bleed.(82%) showed no haemorrhagic manifestations. 
 All the patients who were serologically positive for dengue IgM ELISA were 
chosen out of which 21(42%) tested positive for NS1 antigen also. 
 The common haematological abnormalities encountered were 
thrombocytopenia in 48(96%) patients, leucopenia in 22(44%) of patients, 
followed by anemia in 14(28%) of patients. 
 Thrombocytopenia  observed: Grade 1 was 12(25%), Grade 2 was 
5(10.42%)Grade 3 was 22( 45.83%) and Grade 4 9(18.75%). 
 Leukopenia with reversal of neutrophil lymphocyte ratio was seen in 6(12%) 
of the patients. 
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 Abnormalities in liver function parameters(hepatitis) was the most common 
biochemical  abnormality detected.  Hyperbilirubinemia was detected in 
12(24%) of the patients, raised AST(SGOT) in 39 (78%) and  raised ALT 
(SGPT) in 38(76%) of patients. 
 Coagulation profile derangements were as follows: Prolonged prothrombin 
time (PT- INR) was detected in 7(14%) of the patients and elevated aPTT 
was seen in 10(20%) of the patients. 
 Renal function abnormalities including raised blood urea was seen in 
10(20%) of the patients and elevated creatinine levels were detected in 
9(18%) of the patients.  
 The number of patients who received platelet transfusion were 43(86%). 
 The common indication for platelet transfusion was moderate to severe 
thrombocytopenia followed by bleeding tendencies. 
 Most of the patients, 26(52%) out of fifty were initiated platelet transfusion on 
the second day following admission.  The number of platelets transfused 
ranged from 1-10 units, but most of them 27(54%) received only 1-2 units of 
platelets. 
 Normalization of platelet count for those who received platelet transfusion 
occurred between 2-6 days after initiation of transfusion.  The commonest 
being on the third day,23(53.49%) out of 43 patients. 
 None of the patients who received platelet transfusion developed any form 
of transfusion reaction in our study 
 The average duration of hospital stay was 8.7 days. 
 None of the patients developed Dengue Shock Syndrome(DSS) and all the 
patients made a complete recovery. 
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PARTICIPANTS INFORMED CONSENT FORM 
 
            The details of the study have been explained to me in writing  and the 
details have been fully explained to me. I  an aware that the results of the study 
may not be directly beneficial to me but will help in the advancement of medical 
sciences. I confirm that I have read and understood the information sheet for 
the above study and had the opportunity to ask questions.  I understand that my 
participation in the study is voluntary and I am free to withdraw at any time 
without giving any reason, without medical care that will be normally provided 
by this hospital being affected.    I  agree not to restrict use of any data or 
results that arise from this study provided such a use is only for scientific 
purpose(s).I  have been given an information sheet giving the details of the 
study .I fully consent to participate in the study titled “Dengue: A 
Clinicohaematological  profile and role of platelet transfusion in its 
management.’’ 
 
Serial Number/ Reference No : 
 
Name of the Participant  :                              
 
Address of the participant  : 
 
Contact number of the participant : 
 
                                                                                      
Signature/ Thumb impression of the  participant/ Legal guardian  
(if below 18 years) 
 
    Witness 1  : 
 
    Witness 2 : 
 
    Date :  
 
    Place  :                                    
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PROFORMA 
 
Dengue: A Clinicohematological Profile and Role of Platelet Transfusion 
in Its Management 
 
 
Name of the Patient:      OP No.:  
 
Age   :      IP No.: 
 
Sex   :      DOA : 
 
Occupation  :      DOD : 
 
Address  : 
 
Chief Complaints :  
 
 
History of Presenting Illness:  
 
(A) Constitutional Symptoms  
1. Fever    :  Present  ; Absent  
2. Duration of Fever   :             days  
3. Musculoskeletal Symptoms  
Headache   :  Present  ; Absent  
Retroorbital Pain  : Present  ; Absent  
Myalgia    : Present  ; Absent  
Arthralgia    : Present  ; Absent  
 
4. Symptoms of Spontaneous Bleeding  
Skin petichaes   : Present  ; Absent  
Ecchymosis   : Present  ; Absent  
Epistaxis    : Present  ; Absent  
Oral bleed   : Present  ; Absent  
Hemoptysis   : Present  ; Absent  
Hemetemesis   : Present  ; Absent  
Melena    : Present  ; Absent  
Hematuria   : Present  ; Absent  
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5. Respiratory Symptoms  
URTI    : Present  ; Absent  
LRTI    : Present  ; Absent  
Dyspnoea   : Present  ; Absent  
 
6. Gastrointestinal Symptoms  
Abdominal pain  : Present  ; Absent  
Diarrhoea   : Present  ; Absent  
Vomiting   : Present  ; Absent  
 
7. Other Manifestation  
Family History: 
 
Personal History  : 
     Diet  :  Sleep : 
     Appetite :  Habits :  
     Bowl and Bladder: 
 
Treatment History : 
 
 
History of Underlying Illness: 
 
General Physical Examination  
 
Pallor :  Icterus:   Cyanosis : 
Clubbing :  Lymphadenopathy:  Oedema :  
Maculopapular Rash:  
Petichaes :  
 
Vitals 
 
Pulse Rate:    Respiratory Rate:  
Blood Pressure:    Temperature:  
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Systemic Examination  
 
Cardiovascular System  : 
 
Respiratory System  :  
 
Abdomen    :  
 
Central Nervous system :  
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INVESTIGATIONS 
 
Hematological Parameters  
1. NS1 Antigen  : Positive   Negative  
2. IgM Antibody  : Positive   Negative  
3. Hemoglobin  : gm% 
4. Packed Cell volume  
Hematocrit  : Significant   Insignificant  
Rising titre  : Present   Absent  
5. Total WBC count :   cumm/L 
6. Differential WBC count 
Polymorphs  : 
Lymphocytes  : 
Eosinophils  :  
Basophils   :  
Monocytes  :  
Other forms  : 
7. Platelet count  :   cumm/L  
8. Peripheral Smear : 
 
Biochemical Parameters  
1. AST :    S.Bilirubin        :  
2. ALT :    BUN                 :  
3. aPTT :    S.Creatinine      : 
4. PT  :    Blood glucose   : 
 
Other Parameters  
1. Chest Radiograph: 
 
 
2. Ultrasonography of Abdomen and Pelvis:  
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Vital Statistics 
A. Signs of Capillary Leak : Present    Absent   
 (Raising Hematocrit,  
 Ascites, Pleural Effusion) 
B. Hemorrhagic Manifestation : Present    Minor    
      Major    Absent  
C. Significant Shock  : Present    Absent   
 
GRADING OF DENGUE FEVER 
 
1. Dengue Fever (DF)      
2. Dengue Hemorrhagic Fever (DHF)    
3. Dengue Shock Syndrome (DSS)    
 
 
PLATELET TRANSFUSION DETAILS(IF GIVEN) 
 
I.  Platelet Transfusion    : Done   Not Done  
II.  Indication for Platelet Transfusion      : 
III.  Level of Thrombocytopenia at Which 
 Platelet Transfusion was Initiated   : 
IV. Day at Which Platelet Transfusion was Initiated  
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V Patients Response to Platelet Transfusion 
 
 
 
No of  
Days 
 
0 1 2 3 4 5 
Units of platelet transfused 
      
Patient’splatelet Count 
      
 
VI.  Adverse Events Related to platelet Transfusion :  
 
  
 
 
FINAL OUTCOME 
 
   
 
Recovered    
 
 
Expired   
 
 
 
 
 
 
Date:         
 
Place: 
 
 
 
 
Signature of Researcher 
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1.  29 F 6 days 7 + - - - - - - - - - - - - - - - - - - 
2.  47 M 8 days  9 + - + - - + - - + - + + - - - - - - - 
3.  60 M 5 days 7 + - + - - - - - - - - - - - - - - - - 
4.  41 M 5 days 6 + - + - - - - - + - + - - - - - - - - 
5.  44 M 10 days 12 + - + - - - - - + - - - - - - - - - - 
6.  14 M 5 days 8 + - + - - - - + - + + + - - - - - - - 
7.  27 F 6 days 6 + - + - - - - - + - - + - - - - - - - 
8.  32 M 7 days 8 + + + - - - - - - - + - - - - - - - - 
9.  27 F 5 days 6 + - + - - - - - - - + - - - - - - - - 
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10.  38 F 6 days 7 + - + - - - - - + - + + - + - - + + - 
11.  15 F 7 days 8 + - + - - - - - + - + + - + - + - + - 
12.  22 F 6 days 7 + - - - - - - - + - + - - - - - - - - 
13.  39 M 5 days 7 + - - - - - - - - - + + - - - - - - - 
14.  24 M 6 days 7 + - - + - - - - + - + - - - - - - - - 
15.  68 M 5 days 6 + - - - - - - - - - + - - - - - - - - 
16.  15 F 5 days 7 + - + - - - - - - - + + - - - - + + - 
17.  33 M 6 days 7 + - + - - - - + + - + - - - - - - - - 
18.  39 M 10 days 11 + - + - - - - - - - - - - + - + + - - 
 
 
ANNEXURE-II (MASTER CHART) 
S
l.
 N
o
 
A
g
e
 
S
ex
 
D
u
ra
ti
o
n
 o
f 
fe
v
er
 
D
a
y
 o
f 
D
is
ch
a
rg
e 
CLINICAL FEATURES 
Haemorrhagic 
manifestations 
Signs of Capillary Leak 
Musculoskeletal Respiratory Gastrointestinal Present Absent 
Pleural 
effusion 
Ascites 
Rise of 
heamato
crit 
Shock 
H
ea
d
a
ch
e
 
R
et
ro
o
rb
it
a
l 
p
a
in
 
M
y
a
lg
ia
 
A
rt
h
ra
lg
ia
 
U
R
T
I 
L
R
T
I 
D
y
sp
n
o
ea
 
A
b
d
o
m
in
a
l 
p
a
in
 
V
o
m
it
in
g
 
D
ia
rr
h
o
ea
 
H
ep
a
to
m
eg
a
ly
 
S
p
le
n
o
m
eg
a
ly
 
M
a
jo
r
 
M
in
o
r
 
     
19.  70 M 6 days 7 + - + - + + - - - - + + - + - - + - - 
20.  16 M 7 days 8 + - - - - + - - - - - + - - - - - - - 
21.  31 M 6 days 7 + - + - + + - - - + - + - - - - + + - 
22.  27 M 5 days 7 + - - + - + - + + - + + - + - - + - - 
23.  62 F 5 days 7 + + - + - - - + + - + + - + - + + - - 
24.  18 M 7 days 8 + + + - + + - - - - + - - - - - - - - 
25.  55 F 7 days 8 + - + - - - - + + - - - - - - + + - - 
26.  30 F 5 days 7 + - + - - - - - + - + + + - - - - - - 
27.  44 M 6 days 7 + - + - - - - - - - - + - - - - + + - 
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28.  65 M 7 days 8 + - - + - - - - - - - + - - - - - - - 
29.  36 F 6 days 9 + - + - - - - + + - - - - - - - - - - 
30.  17 M 7 days 9 + - + - - - - - - - - - - - - - - - - 
31.  27 M 6 days 8 + - + - - - - - - - - - - - - - - - - 
32.  19 M 5 days 7 + - + - - - - - - - + + - - - - - - - 
33.  60 F 7 days 8 + - + - - - + + +  + + - - - - - - - 
34.  29 M 8 days 10 + - + - - - - - - + - - - - - - - - - 
35.  38 F 6 days 8 + - + - - - - - - + - + - - - - - - - 
36.  47 F 10 days 12 + - + - - - + - - - - - - - - - - - - 
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37.  19 M 6 days 7 + - + - - - +  + + - + - - - - - - - 
38.  29 F 7 days 9 + - + + - - + + - - - - - - - - - - - 
39.  21 M 5 days 7 + - + - - - - - + + - + - - - - + + - 
40.  34 F 6 days 7 + - + - - - + + +  - - - - - - - - - 
41.  40 M 10 days 12 + - + - + + - - + + - + - + - + + - - 
42.  68 F 6 days 7 + - + - + - - - - - - - - - - - - - - 
43.  23 M 6 days 8 + + + - + + - - + - - - - - - - - - - 
44.  32 F 7 days 9 + - + - - - - + - - - - - - - + + - - 
45.  30 M 7 days 8 + - + - - - - - - + - + - - - - - - - 
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46.  45 F 5 days 7 + - + - - - - - - + - + - - - + - +  
47.  76 F 7 days 14 + + + - - - + + - - - - - - - - - + + 
48.  39 M 6 days 8 + - + - - - + + - - - - - - - - - - - 
49.  36 F 8 days 9 + + + - - - - - + + - + - + - - - - - 
50.  45 M 9 days 10 + + + - - - + - - - - - - + - - + + - 
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Haematological Parameters Biochemical parameters  
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1.  + + 10.9 32.1 9700 57.9 32.3 2.2 7 0.5 232000 NNA,WBC-
WNL,P-Ad 
32 34 0.6 18 0.6 31 92 1.0  - - - - - - DF Recovered 
2.  - + 13.6 38.1 4500 57.2 31.9 0.5 9.9 0.5 33000 NN,P-↓ 23 32 8 36 1.1 32 73 1.0   0  2 3 - DHF Recovered 
3.  - + 13.1 32.2 7400 61.8 19.3 0.8 16 2.1 48000 NN,P-↓ 86 101 2.1 45 1.9 38 433 1.0  - - - - - - DF Recovered 
4.  - + 12.8 34 5500 54.8 17.8 0.9 14.9 1.7 67000 NN,P-↓ 38 68 0.3 22 0.8 29 167 1.0  - - - - - - DF Recovered 
5.  - + 12.4 32.8 2300 46.5 33.6 6.6 13.1 0.4 137000 NN,P-↓ 86 104 1 17 1.3 31 103 1.0  - - - - - - DF Recovered 
6.  + + 17.4 51 5500 59.9 30.8 0.8 6.9 1.6 21000 NN,P-↓ 160 227 0.7 35 0.9 38 144 1.07   0  5 6 - DHF Recovered 
7.  - + 12.1 29 2300 74 13.6 1.1 11 0.3 125000 NN,WBC-↓,P-↓ 52 75 0.3 18 0.7 32 117 1.1   3  1 4 - DF Recovered 
8.  + + 14.2 34 3700 42 36 4.0 16 0.9 62000 NN,P-↓ 128 214 1.1 28 0.8 36 114 1.2   3  1 2 - DF Recovered 
9.  - + 12.8 33 2800 47.4 37.2 0.8 13.4 1.2 84000 NN,WBC-↓,P-↓ 56 58 0.9 19 0.7 31 122 1.0   3  1 3 - DF Recovered 
10.  - + 14.4 41.7 1400 40.4 49.0 1.2 7.6 1.8 56000 NN,WBC-↓,P-↓ 182 265 0.5 17 0.7 34 341 1.0   3  2 4 - DHF Recovered 
11.  - + 11.8 41 3800 65.5 20.7 0.9 12.9 1.0 79000 NN,WBC-↓,P-↓ 211 142 0.8 17 0.9 38 129 1.0   2  3 5 - DHF Recovered 
12.  + + 11.5 36 3300 60.7 31.4 1.9 3.9 2.1 41000 MH,WBC-↓.P-↓ 40 32 0.4 36 0.9 30 126 1.0   1  1 3 - DF Recovered 
13.  - + 10.8 33 3600 66.9 15.0 1.0 16.1 1.0 34000 MH,WBC-↓.P-↓ 85 278 1.4 34 1.3 32 142 1.0   1  2 3 - DF Recovered 
14.  + + 14 34 1500 66.5 21.3 1.9 9.8 0.5 31000 NN,WBC-↓,P-↓ 73 32 0.8 25 0.9 32 99 1.0   1  1 3 - DF Recovered 
15.  - + 12.5 37 2600 54.5 32.6 0.7 10.8 1.4 34000 NN,WBC-↓,P-↓ 24 157 1.0 17 1.0 40 158 1.0   1  1 3 - DF Recovered 
16.  + + 12.1 37.9 3600 33.8 48.4 0.5 11.8 5.5 60000 NN,WBC-↓,P-↓ 48 29 0.8 34 0.7 28 127 1.0   2  1 3 - DHF Recovered 
17.  + + 10.9 32.0 6400 62.2 12.5 4.0 20.7 0.6 106000 NNA,WBC-N,P-↓ 87 34 2.4 16 0.6 44 84 1.0  - - - - - - DF Recovered 
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18.  - + 10.7 28 9600 48 34 0.8 14.8 2.3 10000 MHA,WBC-↓.P-↓ 58 63 0.8 89 1.7 52 125 3.2   1  5 6 - DHF Recovered 
19.  - + 13.0 33.0 6200 63 22 3.8 9.5 1.4 19,000 NN,WBC-↓,P-↓ 33 80 3.7 68 1.2 38 128 1.07   1  5 4 - DHF Recovered 
20.  - + 10.4 33.0 7500 32.9 52.2 0.6 11.8 0.8 1,23,000 MHA,WBC-N,P-↓ 64 46 0.8 26 0.7 32 110 1.0   3  2 5 - DHF Recovered 
21.  - + 13.7 40.9 3300 50.9 31.7 1.5 15.5 0.9 27,000 NN,WBC-↓,P-↓ 221 351 3.3 34 0.8 30 131 1.0   1  4 3 - DF Recovered 
22.  - + 15.0 27.6 6300 27.6 63.3 0.4 7.5 0.9 34,000 NN,WBC-N,P-↓ 62 64 2.9 48 1.4 50 73 1.27   1  4 3 - DHF Recovered 
23.  + + 11.9 38.8 1200 58.9 30.1 1.7 6.4 2.9 25,000 NN,WBC-↓,P-↓ 115 58 1.2 18 0.9 37 101 1.07   1  5 6 - DHF Recovered 
24.  - + 10.9 30.5 9000 53.8 32.0 0.4 12.1 1.7 41,000 NNA,WBC-N,P-↓ 27 21 2.3 45 0.9 32 85 1.0   1  1 3 - DF Recovered 
25.  - + 14.3 39.7 4000 50.1 27.7 0.7 18.7 2.8 18,000 NN,WBC-N,P-↓ 98 58 2.8 47 1.0 98 368 0.8   1  3 4 - DHF Recovered 
26.  + + 10.3 31.0 7700 59.9 19.9 3.3 7.1 0.3 98,000 MHA,WBC-N,P-↓ 122 136 0.8 72 6.4 32 86 1.4   1  10 4 - DHF Recovered 
27.  + + 14.6 45 2900 40.5 30 12.8 15.7 0.8 35,000 NN,WBC-↓,P-↓ 442 336 0.9 16 0.9 46 112 1.2   1  8 6 - DHF Recovered 
28.  - + 13.3 40 5700 49.7 36 2 10.4 0.7 34,000 NN,WBC-N,P-↓ 22 29 1.2 36 0.6 37 131 1.2   1  2 3 - DHF Recovered 
29.  - + 13.2 36 10300 18 50 1 20 11 38,000 NN,WBC-N,P-↓ 171 162 0.6 14 0.8 41 220 1.3   1  1 3 - DF Recovered 
30.  + + 14.8 53 4300 56.2 20.4 1.2 16.9 5.3 35,000 NN,WBC-N,P-↓ 257 87 0.9 26 0.9 26 87 0.9   1  1 3 - DF Recovered 
31.  + + 14.9 48 3800 52 28.1 2.0 15.0 1.9 32,000 NN,WBC-↓,P-↓ 124 319 0.9 13 0.4 39 103 1.2   2  1 3 - DF Recovered 
32.  + + 14.9 49.1 5300 74.1 14.1 3 8.3 0.5 1,01,000 NN,WBC-N,P-↓ 134 125 1.2 20 0.7 30 140 1.0   2  1 3 - DF Recovered 
33.  - + 10.9 30.4 4600 48.3 39.7 0.8 9.8 1.3 32,000 NNA,WBC-N,P-↓ 66 49 0.7 24 0.9 35 142 0.9   2  2 3 - DF Recovered 
34.  - + 12.4 32.8 2300 46.5 33.6 0.4 13.1 0.4 1,37,000 NN,WBC-↓,P-↓ 86 104 1.0 17 1.3 31 103 1.0   2  2 2 - DF Recovered 
35.  + + 17.4 51 5500 59.9 30.8 0.8 6.91 1.6 21,000 NN,WBC-N,P-↓ 160 227 0.7 35 0.98 38 144 1.0   1  5 6 - DHF Recovered 
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36.  - + 12.1 29 2300 74 13.6 1.1 11 0.3 1,25,0000 NN,WBC-↓,P-↓ 52 75 0.3 18 0.7 32 118 1.0   3  1 4 - DF Recovered 
37.  + + 12.5 37 2600 54.5 32.6 0.7 10.8 1.4 34,000 NN,WBC-↓,P-↓ 224 157 1.0 17 1.0 40 158 1.0   1  1 3 - DF Recovered 
38.  - + 10.8 33 3600 66.9 15.0 1.0 16.1 1.0 34,000 MHA,WBC-↓,P-↓ 85 278 1.1 34 1.3 32 142 1.0   1  2 4 - DF Recovered 
39.  + + 12.1 37.9 3600 33.8 48.4 0.5 77.8 5.5 60,000 NN,WBC-↓,P-↓ 48 29 0.8 34 0.7 28 127 1.0   2  1 3 - DHF Recovered 
40.  + + 10.9 32 6400 62.2 12.5 4.0 20.7 0.6 1,60,000 MHA,WBC-N,P-N 87 34 2.4 16 0.6 44 84 1.0  - - - - - - DF Recovered 
41.  - + 10.7 28 9600 48 34 0.8 14.8 2.3 10,000 NNA,WBC-N,P-↓ 58 63 0.8 89 1.7 52 125 3.2   1  5 2 - DHF Recovered 
42.  - + 13.0 33 6200 63 22 3.8 9.5 1.4 19,000 NN,WBC-N,P-↓ 33 80 3.7 68 1.2 38 128 1.0   1  5 3 - DHF Recovered 
43.  - + 10.9 30.5 9000 53.8 32 0.4 12.1 1.7 41,000 MHA,WBC-N,P-↓ 27 21 2.3 45 0.9 32 85 1.0   1  1 3 - DF Recovered 
44.  - + 14.3 39.7 4000 50.1 27.7 0.7 18.7 2.8 18,000 NN,WBC-N,P-↓ 98 58 2.8 47 1.0 38 368 1.1   1  3 4 - DF Recovered 
45.  + + 10.1 31 7800 69.9 19.9 3.3 7.1 0.3 98,000 MHA,WBC-N,P-↓ 122 136 0.8 72 6.4 32 86 1.1   1  8 4 - DHF Recovered 
46.  + + 14.0 42 2900 40.5 30 12.8 15.7 0.8 35,000 NN,WBC-↓,P-↓ 422 336 0.9 16 0.9 46 112 1.2   1  6 5 - DHF Recovered 
47.  - + 13.3 40 5700 49.7 36 2 10.4 0.7 34,000 NN,WBC-N,P-↓ 20 29 1.2 36 0.6 37 131 1.2   1  2 3 - DF Recovered 
48.  - + 13.2 36 10300 18 50 1 28 3 38,000 NN,WBC-N,P-↓ 171 162 0.6 14 0.8 41 220 1.3   1  1 3 - DF Recovered 
49.  + + 14.2 34 3700 42 36.2 4.0 16 0.9 38,000 NN,WBC-↓,P-↓ 128 214 1.1 28 0.8 36 114 1.2   2  1 3 - DF Recovered 
50.  + + 12.8 33 2800 47.4 37.2 0.8 13.4 1.2 84,000 NN,WBC-↓,P-↓ 56 58 0.9 19 0.7 31 122 1.0   3  1 3 - DF Recovered 
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DF  - DENGUE FEVER 
 
DHF  - DENGUE HAEMORRHAGIC FEVER 
 
DSS  - DENGUE SHOCK SYNDROME 
 
NS 1  - NON STRUCTURAL PROTEIN 1 
 
WBC   - WHITE BLOOD CELL 
 
SEA  - SOUTH EAST ASIA  
 
TNF  - TUMOUR NECROSIS FACTOR 
 
WHO  - WORLD HEALTH ORGANISATION 
 
DALYS - DISABILITY ADJUSTED LIFE YEARS 
 
CFR  - CASE FATALITY RATE 
 
DV  - DENGUE VIRUS 
 
RNA  - RIBONUCLEIC ACID 
 
RT-PCR - REVERSE TRANSCRIPTASE POLYMERASE CHAIN  
REACTION 
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SGPT  - SERUM GLUTAMIC PYRUVATE TRANSAMINASE 
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IMMUNOSORBENT ASSAY 
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